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ABSTRACT
Mast cells are classically recognized as the effector cells of Immunoglobulin E
(IgE)-mediated hypersensitivity reactions (i.e. allergic reactions). Mast cells also play an
important role in the innate immune response to parasitic helminth infection. Allergic
disease including allergic rhinitis, asthma, atopic dermatitis, and anaphylaxis, is a major
health concern in the United States with greater than 60 million Americans suffering
from allergy and asthma. In addition, mast cells have more recently been implicated in
non-allergic disease including various human cancers, which will affect approximately
39.6% of U.S. men and women. Therefore, understanding the immunological and
molecular mechanisms that regulate mast cells is vital to our understanding of their role
in both allergic and non-allergic disease in humans. In this study, we identified novel
mechanisms that regulate FcεRI-induced biosynthesis of inflammatory Prostaglandin D2
(PGD2) from in situ-matured mast cells from human skin. Specifically, we demonstrated
that interleukin-6 (IL-6), a classical pro-inflammatory cytokine, is a positive regulator,
whereas Resveratrol, a natural polyphenol found in the skin of red grapes, is a negative
regulator of PGD2 biosynthesis. We demonstrate that Resveratrol at relatively low
concentrations specifically inhibited the production of PGD2 without affecting
degranulation. Mechanistically, Resveratrol inhibited the expression of cyclooxygenase-2
(COX-2), an enzyme in the arachidonic acid pathway that is directly involved in PGD2
biosynthesis, but had no effect on phosphorylation of Syk kinase, which is a critical
protein in mast cell degranulation. In contrast, IL-6 enhanced FcεRI-induced COX-2
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expression leading to increased PGD2 biosynthesis. In support of this, we showed
that FcεRI and gp130 (the signaling portion of the IL-6 receptor) signals cooperate to
enhance STAT-3 phosphorylation, a key event in the IL-6 receptor signal pathway.
Moreover, inhibition of IL-6-induced phosphorylation of STAT-3 with the specific
inhibitor C188-9 also attenuated the increased production of PGD2. Thus, IL-6
potentiates PGD2 production by a STAT-3-dependent mechanism. Jointly, these data
demonstrate that Resveratrol is a negative regulator, and IL-6 a positive regulator of
FcεRI-induced PGD2 biosynthesis from human skin mast cells. We further demonstrate
that IL-6 induced the expression of vascular endothelial growth factor (VEGF), a major
regulator of angiogenesis, from human skin mast cells also by a STAT-3-dependent
mechanism. Lastly, we demonstrated by proteome profiling analysis that human skin
mast cells spontaneously secrete several angiogenesis-related proteins – CXCL16,
DPPIV, Endothelin-1, GM-CSF, IL-8, MCP-1, Pentraxin 3, Serpin E1, Serpin F1, TIMP1, Thrombospondin-1, uPA, and VEGF – at relatively high concentrations. The array data
was verified by specific enzyme linked immunoassay (ELISA). This novel data suggests
an innate role for mast cells in both human tumorigenesis and normal development of
human vasculature. Together, these novel findings enhance our understanding of the
mechanisms that regulate the release of allergic mediators from mast cells, and suggest a
possible role for mast cells in oncogenesis and normal vascular development.
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CHAPTER 1
INTRODUCTION
Recently, mast cells have been implicated in many non-allergic diseases in which
chronic inflammation plays a vital role (1–3). While they are traditionally viewed as the
effector cells of IgE-mediated hypersensitivity responses, mast cells undoubtedly have
yet undefined functions outside of these mechanisms. One of the most critical areas of
mast cell biology to understand is the modulation of inflammatory mediator release. Due
to their ability to produce and release robust quantities of many different chemical
mediators, mast cells can affect a wide variety of processes such as cell migration, vessel
formation and dilation, airway constriction, and mucous production (4).
1.1 MAST CELLS
Mast cells are hematopoietic immune cells that function as the effector cells of the
allergic reaction in addition to participating in the innate immune response against
infection (5). Mast cells can be characterized by three distinct features: the surface
expression of the high-affinity IgE receptor FcεRI, surface expression of the stem cell
factor (SCF) receptor, and numerous cytoplasmic granules containing pre-formed
inflammatory mediators (6). These tissue-resident sentinel cells use their complement of
chemical mediators to induce and modulate a wide range of physiological processes
including anaphylaxis, angiogenesis, and wound-healing (7).
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Mast cell development begins in the bone marrow where hematopoietic stem cells
develop into multipotent progenitors. The multipotent progenitors then undergo
commitment into mast cell progenitors (MCp) through careful transcriptional control.
MCps are then released into circulation already both c-kit and FcεRI positive, but are
nearly unidentifiable by classical staining due to their reduced or non-existent granularity.
From circulation, MCps home to the peripheral tissues, particularly to areas that directly
contact the external environment and around vessels, where they become resident and
mature in-situ (8, 9). During the process of migration, maturation, and survival of the
mast cell progenitors, the cytokine stem cell factor (SCF) is indispensable (10). SCF is
the ligand for c-kit (CD117), and binding of the receptor leads to the activation of the
JAK/STAT, PI3K/AKT/mTOR, and RAS/RAF/MAPK pathways (11). Together, the
gene products of these pathways cooperate to trigger mast cell proliferation, migration,
and progression through the cell cycle (12). SCF is also necessary for mast cell survival
(13). It has also been shown that SCF is necessary for murine mast cells to develop a full
complement of cytoplasmic granules (14, 15).
Once mature, mast cells are generally considered to be very long-lived (6).
Interestingly, mature tissue mast cells are believed to be terminally differentiated and
thus do not normally undergo cell division and proliferation (8). Mast cells also tend to
exhibit heterogeneity that seems to be influenced by the tissue in which they mature (16,
17). This is most evident in the enzyme content of their granules, as human lung mast
cells express only tryptase (MCT) while human skin mast cells contain both tryptase and
chymase in their granules (MCTC) (18). In the border tissues, the main role of mast cells
is to become sensitized to invaders by binding IgE with FcεRI, enabling them to react to
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exposure from foreign compounds. The pathway initiated by FcεRI crosslinking (XL) in
mast cells is complicated, but ultimately results in the release of the cytoplasmic granules
and their mediators, biosynthesis of membrane-derived eicosanoids, and de-novo
synthesis of inflammatory proteins (19).
Upon crosslinking by a multivalent antigen and subsequent receptor aggregation,
the immunoreceptor tyrosine-based activation motif (ITAM) on the beta and gamma
chains are phosphorylated by the Src family kinase Lyn. The phosphorylated ITAMs then
act as docking sites to recruit spleen tyrosine kinase (Syk). When Syk binds to the
activated ITAMs on FcεRI it undergoes a change in conformation that results in an
increase in its enzymatic activity. Activated Syk is then autophosphorylated and serves to
phosphorylate the adapter proteins LAT, which subsequently activate the PI3K pathway.
These receptor-proximal signaling events also result in the activation of GTPases like Ras
and Rho, leading to the stimulation of the ERK, JNK, and p38 MAPK pathways.
Ultimately, the resulting increase in intracellular calcium leads to the degranulation
process in which the pre-formed mediator-laden granules are released from the cell. PKC
and MAPK activation also leads to stimulation of cPLA2, which liberates arachidonic
acid from the plasma membrane and induces the mechanism responsible for eicosanoid
production. Finally, de-novo protein production is initiated by activated transcription
factors like NFAT and NFκB proteins that translocate into the nucleus (20).
The complement of chemical mediators produced by mast cells differs from
species to species, and even among subtypes within the same species. Generally
contained within the granules are pre-formed compounds like vasomodulatory histamine
and heparin, but also enzymes like tryptase, chymase, beta hexosamindase, and cathepsin
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G (21).

Eicosanoids like prostaglandin D2 (PGD2) and leukotriene C4 (LTC4) are

synthesized by repurposing plasma membrane components (22). Cytokines, chemokines,
and growth factors including TNFα, IL-6, IL-8, VEGF, GM-CSF, and MCP-1 are
manufactured de-novo when required (23). Together, the chemical mediators induced by
FcεRI XL work to induce the classical symptoms of allergy including increased mucous
production, bronchoconstriction, and vasodilation leading to edema and erythema.
It is important to note that mature mast cells express not only c-kit and FcεRI, but
also express a wide array of receptors including those for pathogen-associated molecular
patterns (PAMP), IgG, neuropeptides, complement factors, eicosanoids, and cytokines
(19). For this reason, mast cells can be activated not only by allergic FcεRI XL, but also
but non-allergic mechanisms. For example, degranulation can also be caused by
chemicals like insect/reptile venoms, endogenous tissue proteases, and complement
factors such as c3/5a (24–26). Accordingly, mast cell mediator release has been shown to
be highly heterogeneous depending on the stimuli and engaged receptor (27). Some
stimuli may trigger all three phases of mast cell mediator release, while others may only
induce degranulation or cytokine production (28). Mast cell activation by FcεRI XL has
been extensively studied, but it is only recently that scientists have begun to shift focus to
the effects of non-antigen stimuli on mast cell function. Specifically, the effects of
cytokine activation on in-situ-matured human mast cells have been poorly characterized
at present.
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1.2 MAST CELLS IN ALLERGIC DISEASE
Allergic disease is characterized by the Centers for Disease Control and
Prevention (CDC) as an overreaction of the immune system to substances that generally
do not affect other individuals. The CDC estimates that nearly 20 million US adults have
been diagnosed with allergic rhinitis in the past year, while about 25 million Americans
suffer from asthma. Broadly, allergic disease includes conditions like asthma, allergic
rhinitis, urticaria, sinusitis, and food allergies. These conditions can each be characterized
by individual clinical presentations, but tend to share a common set of symptoms. Most
allergic diseases display chronic inflammation of some sort, although the inflamed area
differs from condition to condition and confers the complications unique to each disease
(29). According to the Mayo Clinic, those that suffer from asthma typically have airway
inflammation leading to bronchoconstriction, making normal breathing difficult.
Conversely, urticaria, or hives, presents as a superficial skin rash that is sensitive to the
touch and often causes physical discomfort.
Due to the pervasiveness of inflammation in these conditions, mast cells have
long been implicated in the pathogenesis of allergic disease due to their ability to produce
robust amounts of pro-inflammatory mediators. Additionally, it is known that mast cell
numbers are increased in patients with active asthma or allergic rhinitis (5, 30). Several
mast cell mediators have been shown to be causative in effecting the symptoms
characteristic of allergic disease (31). When released, histamine causes powerful
bronchoconstriction and vasodilation while the serine neutral proteases chymase and
tryptase trigger local tissue remodeling (32). Additionally, the production of cytokines
and chemokines cause recruitment and infiltration of immune cells, which leads to the
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perpetuation rather than resolution of inflammation (19). Finally, the arachidonic acidderived eicosanoids released by mast cells contribute to bronchoconstriction and
vasodilation as well as more recently elucidated mechanisms including effector cell
trafficking, antigen presentation, immune cell activation, matrix deposition, and fibrosis
(33). Human mast cells are known to biosynthesize and secrete PGD2 and LTC4, while
murine mast cells are known to produce PGD2, thromboxane B2, and leukotriene B4 (34,
35).
Recently, the eicosanoid PGD2 been chiefly implicated in the pathogenesis and
development of asthma. PGD2 is produced by the liberation of arachidonic acid (AA)
from the plasma membrane by cytosolic phospholipase A2 (cPLA2) in response to
increased intracellular calcium levels caused by inflammatory stimuli. Following
membrane liberation, AA is converted into prostaglandin G2 (PGG2) and subsequently
prostaglandin H2 (PGH2) by either constitutive cyclooxygenase-1 (COX-1) or inducible
cyclooxygenase-2 (COX-2). Hematopoietic prostaglandin synthase (hPGDS) then
metabolizes PGH2 into PGD2 which is released into the extracellular environment
(hPGDS is expressed in hematopoietic immune cells, while lPGDS is expressed in brain,
heart, and adipose tissue). Interestingly, PGD2 is rapidly metabolized once released into
the blood stream, so any effects of the eicosanoid must take place near the cell of origin
(36). Currently, two major PGD2 receptors have been identified: D prostanoid receptor-1
(DP1) and chemoattractant receptor homologous molecule expressed on Th2 cells/D
prostanoid receptor-2 (CRTH2/DP2). Depending on the receptor stimulated on the target
cell, these effects can include immune cell activation and extravasation, vasodilation, and
bronchoconstriction (37, 38). Together, these symptoms represent the classic clinical
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presentation of allergic inflammation. PGD2 is produced by multiple cell types including
those of the heart, brain, and immune system, but it is chiefly recognized as a product of
mast cells. Due to the implication of both mast cells and PGD2 in allergic disease,
therapeutic modulation or blocking of the arachidonic acid pathway in mast cells
represents an important mechanism for understanding and treating allergic disease.
1.3 PROSTAGLANDIN D2 IN ASTHMA PATHOGENESIS
Several studies have pointed towards the importance of PGD2 during the
pathogenesis and persistence of asthma (37–40). This cascade begins when an antigen
presenting cell such as a dendritic cell or macrophage in the airway captures, processes,
and presents antigen to a CD4+ T cell. The T cell is then polarized, generally into a Th2
phenotype, which subsequently releases Th2 cytokines including IL-4, IL-5, and IL-13.
These cytokines lead to eosinophilia, differentiation and proliferation of Th2 cells, airway
hyper responsiveness (AHR), increased mucous production, and class switching in B
cells to produce IgE. This increased IgE binds to the high-affinity IgE receptors FcεRI on
the surface of mast cells, where it allows them to respond to the offending antigen. Once
crosslinked, aggregated FcεRI induces the production and release of inflammatory
mediators including PGD2 (38). Specifically during asthma, allergen challenge induces a
swift and robust production of PGD2, which can culminate in levels about 150-fold
higher than during pre-challenge (38). Notably, it is known that other cell types are
capable of producing PGD2 including dendritic cells and Th2 cells, and it is suspected
that others such as fibroblasts and other airway cells may be involved (38). However,
data from several studies supports the notion that airway mast cells are in fact the main
source of PGD2 during allergic inflammation (22, 38). Together, this data suggests that
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mast cells and their production of PGD2 may link the acute and chronic effects of the
allergic response by initiating the processes leading to the persistence of pulmonary
inflammation.
This theory was tested in several studies by either knocking out or interfering with
DP1/2s ability to bind PGD2 and exert its functional effects. Loss of DP1 in a model of
OVA-induced allergic inflammation led to reductions in Th2 cytokine levels, mucouscontaining cells, as well as lymphocyte and eosinophil infiltration in BALF and lung
tissue compared to controls (37). Another similar experiment examined the effects of
using a DP2 antagonist to inhibit asthma-like pathological changes, resulting in the
conclusion that like DP1, DP2 plays a critical role in allergic inflammation (37).
1.4 RESVERATROL AND MAST CELL FUNCTION
Resveratrol is a natural polyphenol found in dark berries, particularly the skin of
red grapes, and red wine. Under natural conditions, plants produce Resveratrol to help
fight off microbial infection in addition to using it to survive periods of inadequate water
and nutrient supply (41). This stilbenoid has been the subject of many recent studies due
to its reported protective effects against cardiovascular disease, inflammation, cancer, and
aging (42–45). As a direct effect of these reports, Resveratrol is viewed in the general
community as a “magic bullet” that provides numerous unfounded health benefits.
Additionally, the recent resurgence in demand for naturally derived medications has
made Resveratrol a popular nutritional supplement and ingredient in over-the-counter
topical lotions. Most importantly, Resveratrol has demonstrated a plethora of biological
activities both in-vitro and in-vivo such as reduction of cyclooxygenase expression,
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modulation of NFκB activity, and stimulation of cytokine production in CD4+ and CD8+
T cells (46). When taken together, this information suggests a role for Resveratrol in
modulating the greater immune system as a whole.
Since Resveratrol has been shown to have a strong anti-inflammatory effect, it
follows that many researches have been interested in investigating its action on mast cell
function. In fact, there are numerous papers that outline how Resveratrol modulates mast
cell function and mediator production. Resveratrol was shown to dose-dependently
decrease histamine and beta-hex release in rat RBL-2H3 mast cells by attenuating Syk,
PLCγ, and PKC activation. Additionally, in a mouse model of anaphylaxis, Resveratrol
inhibited IgE-mediated degranulation and subsequent histamine release (47). Han et al.
(2015) also reported that Resveratrol attenuated Th2 and TNFα cytokine production in rat
RBL-2H3 mast cells by diminishing phosphorylation of p38, MAPK, ERK, and JNK
caused by FcεRI XL. In a mouse model of asthma, Resveratrol was shown to have
therapeutic effects by decreasing TNFα levels in the bronchoalveolar lavage fluid
(BALF), fibrosis in the airway, and Syk phosphorylation and degranulation in mast cells
(48). In a related model of allergic disease Resveratrol showed protective effects by
inhibiting the formation of atopic-dermatis (AD)-like skin lesions through suppression of
the HMGB1 inflammatory pathway(49). Experiments performed with BMMCs
demonstrated that Resveratrol may be able to suppress IgE-mediated PGD2 production
(50). Finally, research on Resveratrol’s effects on the human mast cell line HMC-1
revealed its ability to attenuate pro-inflammatory cytokine production, COX-2
expression, and ERK and NFκB activation (51). Taken together, these studies strongly
suggest that Resveratrol attenuates mast cell pro-inflammatory mediator production by
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suppressing the activation of kinases and transcription factors important during FcεRI XL
signaling.
While the data produced in these studies is promising, there is a failure to address
the biological action of Resveratrol on mature in-situ-derived human mast cells. Due to
its inclusion in topical lotions, the effect of Resveratrol on human skin mast cells is
particularly important, as this cell population would be readily exposed to Resveratrol
through superficial application.
1.5 IL-6 SIGNALING
IL-6 is a pleiotropic cytokine that is ubiquitously associated with inflammation
(52). Produced in response to infection, tissue damage, or inflammation, IL-6 generated
and released by nearly all immune cells and most stromal cells (53). The IL-6 receptor
complex is composed of two vital parts: the ligand binding portion IL-6Rα and the signal
transducing subunit gp130. IL-6 belongs to a family of several gp130-utilitzing cytokines
including leukemia inhibitory factor (LIF), oncostatin M (OSM), IL-11, ciliary
neurotrophic factor (CNTF), and others (54). Signaling can occur via two different
mechanisms, classical signaling and trans-signaling. Classical signaling involes both
membrane-bound IL-6Rα and gp130, whereas trans-signaling utilizes soluble IL-6Rα
binding to membrane-gp130 (55). The trans-signaling mechanism effectively works to
expand the number of cell types that can respond to IL-6 signaling due to the selective
expression of IL-6Rα on immune cells and near ubiquitous expression of gp130 on most
cell types (56). IL-6 binding leads to receptor dimerization which activates the associated
Janus Kinases (Jaks). These Jaks autophosphorylate themselves as well as gp130, and

10

signal transducer and activator of transcription-3 (STAT-3) will then bind to these
phosphorylation sites and become phosphorylated themselves by Jak. Activated STAT3
then dimerizes and translocates to the nucleus where it regulates transcription of IL-6
responsive genes including suppressor of cytokine signaling-3 (SOCS-3). SOCS-3 works
as a negative feedback mechanism and subsequently inhibits IL-6 signaling by blocking
Jak activation (57). In addition to the Jak/STAT pathway, ligation of the IL-6 receptor
leads to activation of the PI3K/Akt (58) and Ras/Raf/MAPK (59) pathways. Depending
on the target cell, these signals cooperate to regulate processes like B cell antibody
production, T cell differentiation, hematopoiesis, and the acute phase reaction (52). Due
to its ability to influence such a wide range of activities during inflammation, increased
IL-6 levels are associated with many diseases and pathologies in which chronic
inflammation is a hallmark (54, 60, 61). In humans, IL-6 levels are correlated with
severity or pathogenesis of allergic diseases including asthma (62–65), urticaria (66, 67),
and mastocytosis (68, 69) in which mast cells play a key role. The exact role of IL-6 in
allergic disease is not known, but there is precedence for modulation of mast cell
development, survival, proliferation, adhesion, and chemokinesis (3, 70–72). Recently, it
was shown that IL-6 enhanced mast cell proliferation, maturation, and reactivity
following FcεRI XL by suppressing the expression of feedback inhibitor SOCS-3 (73).
1.6 ANGIOGENESIS
Angiogenesis is defined as the formation of new vessels from pre-existing ones,
and serves vital physiological and pathological purposes. Vessel formation is critical
during embryonic development and persists throughout an individual’s life where it can
be central to processes like wound healing and pregnancy in females (74–76).
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Conversely, angiogenesis plays a central role in tumor formation and persistence while
also contributing to inflammatory disease (77, 78).
Angiogenesis is generally initiated in response to stress in the local tissue, which
typically manifests as hypoxia (79). This hypoxic environment can be a result of one or
several factors including physiological growth and development, mechanical disruption
such as surgery, or disease. Regardless, in each case these conditions lead to the
upregulation and release of the chemical mediators responsible for new vessel growth
(80). Generally, hypoxia will trigger the expression of proteases and the transcription
factor hypoxia-inducible factor 1 (HIF-1) which is considered to be the master regulator
of the cellular response to hypoxia (81). HIF-1 will then induce the expression and
subsequent release of pro-angiogenic factors including VEGF and FGF (80). The released
proteases will work to degrade the basement membrane which also results in pericyte
detachment. Released VEGF and other growth factors then bind to the receptors on the
surface of endothelial cells (EC), resulting in the proliferation and migration of ECs along
the factor gradient. As the new vessel branch grows outward, circulating endothelial
progenitor cells will adhere to the area of angiogenesis and participate in new vessel
formation. Angiogenesis is terminated via a negative regulation mechanism in which
VEGF induces delta-like ligand (DLL) 4, which binds to Notch-1 and decreases VEGF
receptor (VEGFR) expression (82). The resulting decrease in VEGFR expression halts
EC proliferation and stops growth of the new vessel. Finally, the local tissue begins to
secrete platelet derived growth factor (PGDF) which binds to its receptors on the ECs and
reduces proliferation and VEGF sensitivity and triggers the attachment of pericytes along
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the external surface of the new vessel. With a newfound blood supply, the local tissue can
now function normally, or in the case of tumors, continue uncontrolled growth (83, 84).
Because the formation of new vessels requires the cooperation of many different
cell types, this complex process is regulated by a slew of molecular signals. In fact,
several dozen angiogenesis-associated factors have been isolated and identified thus far
including growth factors, cytokines, and various enzymes (85). These factors are
comprised of both positive and negative regulators of angiogenesis, and their balance is
linked to the shift from physiological to pathological vessel growth.
Understanding how angiogenesis is regulated represents a very important
objective for effective clinical translation. When considering medical intervention in
angiogenesis there are two scenarios: one in which initiation of therapeutic angiogenesis
can alleviate or repair the effects of tissue damage, and one where inhibiting pathological
angiogenesis can resolve or mitigate its progression (86). Comprehending the role mast
cells play in both of these situations is critical in effectively targeting them to treat human
disease in which controlling new vessel growth is pivotal.
1.7 MAST CELLS IN ANGIOGENESIS
Immune cell contribution towards angiogenesis is not a novel idea, and recent
data suggests that vessel growth and inflammation are dependent on one another, rather
than being mutually exclusive. During inflammation, local immune cells secrete
angiogenic factors that lead to the formation of new vessels. These new vessels lead to
the perpetuation of inflammation by providing new highways for immune cell trafficking
and extravasation into the local tissue. This cyclical pathway provides the mechanism for
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persistent inflammation that characterizes many chronic inflammatory diseases like
rheumatoid arthritis (78, 87). It is known that mast cells tend to accumulate and localize
around tumor sites (1). However, the stimuli for their migration and the function they
perform once resident in the tumor microenvironment (TME) is still contested. Although,
increased concentration of SCF in the TME may provide a clue as to what factor is
recruiting MCp from circulation (88). One theory for their heavy presence in the TME is
the ability of mast cells to produce and release powerful angiogenesis-associated factors.
New vessel formation is vital to tumor growth as the cancer requires increased circulation
to remove waste and provide nutrients as it expands. Additionally, it is accepted that mast
cells can contribute to tissue homeostasis by regulating remodeling, repair, and fibrosis
(89). Thus, a role for mast cells in both developmental and pathological angiogenesis is
supported by the current literature.
Mast cells of different species and phenotypes have been shown to produce FGF2, VEGF-A-D, tryptase, chymase, histamine, heparin, IL-8, TNFα, TGF-β, NGF, uPA,
and matrix metalloproteases (MMP) and their inhibitors (90, 91). All of these compounds
are involved either directly in angiogenesis, or function in the degradation of the
extracellular matrix (ECM) which allows for the formation of new vasculature. In fact, it
has been directly shown that mast cells are potent activators of angiogenesis by using the
chick embryo chorioallantoic membrane (CAM) assay (92). The CAM assay is an
established model for studying neovascularization and allows the researcher to directly
visualize vessel growth. Mast cell-stimulated angiogenesis has also been documented in
many studies utilizing both in-vivo and ex-vivo systems (93–96). Additionally, the
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observation that mast cells are frequently found in close proximity to blood vessels
suggests a role for mast cells in angiogenesis (97).
The studies described here identify novel roles for IL-6 and Resveratrol in the
regulation of mediator release from in-situ-matured mast cells from human ski
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CHAPTER 2
MATERIALS AND METHODS- RESVERATROL PREFERENTIALLY
INHIBITS IGE-DEPENDENT PGD2 BIOSYNTHESIS BUT ENHANCES
TNF PRODUCTION FROM HUMAN SKIN MAST CELLS1
Resveratrol is a natural polyphenol found in the skin of red grapes, dark berries,
and peanuts. This stilbenoid has been reported to have many positive health benefits,
including as an antioxidant, anti-aging, and anti-inflammatory compound. Due to its antiinflammatory reputation, many recent studies have examined its direct effects on immune
cells including mast cells. However, never before have the effects of Resveratrol on insitu-matured humans skin mast cells been examined. The methods detailed in this section
were designed to assess the toxicity of Resveratrol on human skin mast cells, in addition
to its effects on degranulation, cytokine production, gene expression, and eicosanoid
biosynthesis. Studies were performed on in-situ-matured human skin mast cells that were
isolated in accordance with the University of South Carolina Internal Review Board
(IRB).
2.1 ISOLATION AND PURIFICATION OF HUMAN SKIN MAST CELLS
Human skin mast cells were isolated and purified from fresh surgical specimens
of human skin tissue obtained from the Cooperative Human Tissue Network of the
National Cancer Institute, as approved by the human studies Internal Review Board at
1

Parts of this section have been excerpted from the following research article:
Shirley, D., C. McHale, and G. Gomez. 2016. Resveratrol preferentially inhibits IgE-dependent
PGD2 biosynthesis but enhances TNF production from human skin mast cells. Biochim. Biophys.
Acta - Gen. Subj. 1860.
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University of South Carolina. The tissues were mechanically disrupted with
surgical scissors and then digested 3 × 1 h at 37 °C with collagenase type II (Worthington
Biochemical, Lakewood, NJ), hyaluronidase from bovine testes, and DNase I (SigmaAldrich, St. Louis, MO) in HBSS wash buffer (1X HBSS, 0.04% NaHCO3, 1% fetal
bovine

serum,

1%

HEPES,

0.1%

CaCl2)

containing

amphotericin

B

and

antibiotic/antimycotic solution. After each digestion period, the samples were filtered
through 40 μm nylon cell strainers. The filtered cells were collected by centrifugation,
washed and re-suspended with wash buffer. After the final digestion, the collected cells
were separated on Percoll by density centrifugation. The cells at the interface of buffer
and Percoll layers were collected, washed and re-suspended at 5 × 105 cells/ml in serumfree X-VIVO 15™ media (Lonza, Walkersville, MD) containing recombinant human
stem cell factor (SCF, 100 ng/ml) (PeproTech, Rocky Hill, NJ). The cells were
transferred onto 24-well plates and maintained under standard culture conditions (37 °C,
5% CO2) with weekly media changes. Purity was assessed cytochemically by
metachromatic staining with acidic toluidine blue. Greater than 95% purity was achieved
by 6 weeks of culture, and the mast cells were used in experiments after 8 weeks. A
schematic of this process is shown in Figure 2.1.
2.2 VIABILITY ASSAY
Mast cell viability was determined by MTT reduction assay using the
TACS® MTT Cell Proliferation Assay from Trevigen (Gaithersburg, MD) according to
the manufacturer’s instructions. Briefly, human skin mast cells were plated in triplicate at
105cells/well of a 96-well plate in 100 µl X-VIVO media + SCF. Resveratrol or DMSO
was added, and the cells were incubated for 24, 48, or 72 h under normal culture
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conditions (37°C, 5% CO2). MTT Reagent was added to the cells and incubated for an
additional 4 h. Detergent was added and the plate was incubated overnight at room
temperature. Absorbance values at 570 nm were acquired with a BioTek Synergy HT
microplate reader (BioTek, Winooski, VT).
2.3 MAST CELL ACTIVATION
Sensitized human skin mast cells (106/ml) were activated by crosslinking FcεRI
with the hapten 4-hydroxy-3-nitrophenylacetyl conjugated to bovine serum albumin at a
16:1 molar ratio (NP-BSA; Biosearch Technologies, Novato, CA) at 37 °C. For
sensitization, 106 cells/ml were incubated in X-VIVO 15™ media or Tyrode's buffer
(135 mM NaCl, 1 mM MgCl2, 20 mM Hepes, 5 mM KCl, 1.8 mM CaCl2, 5.6 mM
glucose; pH 7.4, 0.05% bovine serum albumin) containing 1 μg/ml chimeric human antiNP IgE (human Fc + mouse Fab) (clone JW8/1; AbD Serotec, Raleigh, NC) for 3 h at
37 °C. After washing to remove unbound IgE, the mast cells were re-suspended at
106 cells/ml in X-VIVO 15™ media or Tyrode's buffer, pre-treated with Resveratrol
(Sigma-Aldrich, St. Louis, MO) or DMSO (vehicle) for 1 h at 37 °C, and then activated
with 100 ng/ml NP-BSA for the indicated amount of time.
2.4 β-HEXOSAMINIDASE AND PGD2 ASSAYS
Human skin mast cells were activated with 100 ng/ml NP-BSA for 30 min at
37 °C in Tyrode's buffer. After the incubation period, the mast cells and buffer were
separated by centrifugation (2000 rpm × 5 min) in an Eppendorf 5424 centrifuge, and the
pelleted cells were lysed with an equal volume of 1% Triton X-100. β-Hexosaminidase
activity in supernatant and cell lysate was assayed by measuring the release of pnitrophenol from substrate p-nitrophenyl N-acetyl-β-D-glucosaminide (pNAG; Sigma-
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Aldrich, St. Louis, MO) as described (98, 99). In a 96-well plate, 5 μl of supernatant or
lysate were mixed with 45 μl of 4 mM p-nitrophenyl N-acetyl-β-D-glucosaminide
(pNAG) in citric acid buffer (pH 4.5) and incubated for 1 h at 37 °C. The reaction was
stopped by adding 150 μl of 0.2 M glycine, pH 10.7. Absorbance values at 405 nm were
acquired with a BioTek Synergy HT microplate reader (BioTek, Winooski, VT). Percent
degranulation was calculated as percent release of β-hexosaminidase using the formula:
% β-hex release = ((supernatant) / (supernatant + lysate)) × 100. PGD2 in the supernatant
was measured with a commercial enzyme immunoassay kit (Cayman Chemical, Ann
Arbor, MI) according to the manufacturer's instructions.
2.5 CYTOKINE ELISA
Sensitized human skin mast cells were activated with 100 ng/ml NP-BSA for 3 h
at 37 °C in X-VIVO 15™ media containing SCF and 100 μg/ml soybean trypsin inhibitor
(SBTI; Sigma-Aldrich, St. Louis, MO). After the activation period, the mast cells and
media were separated by centrifugation (2000 rpm × 5 min). IL-6 or TNF in supernatant
was quantified by enzyme-linked immunosorbent assay (ELISA) in a 384-well format as
described (100). Capture (purified) and detection (biotinylated) rat antibodies (BD
Biosciences) used were: IL-6 (MQ2-13A5 and MQ2-39C3), TNF (MAb1 and MAb11).
Serially diluted recombinant cytokine standards (BD Biosciences, San Jose, CA) were
used to generate standard curves. After developing with the substrate for peroxidase 2,2′azino-bis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS; Sigma-Aldrich, St. Louis, MO),
absorbance values at 405 nm were obtained and cytokine concentrations in experimental
samples determined with a BioTek Synergy HT microplate reader (BioTek, Winooski,
VT) and Gen5 Data Analysis Software.

19

2.6 QUANTITATIVE REAL TIME PCR
Cytokine and COX gene expression was determined from sensitized human skin
mast cells activated with 100 ng/ml NP-BSA for 3 h or 30 min, respectively. RNA was
isolated with the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was synthesized from
350 ng total RNA with the SuperScript™ III First-Strand Synthesis System (Life
Technologies, Grand Island, NY). The kits were used according to the manufacturer’s
instructions. The PCR reaction mix was composed of 2 µl of cDNA, 1 µl each of sense
and antisense primers (10 µM each) and 12.5 µl of iQ SYBR® Green Supermix (Bio-Rad,
Hercules, CA) in a final volume of 25 µl. A hot-start PCR protocol (95°C × 5 min, (95°C
× 30 sec, 55°C × 30 sec, 72°C × 30 sec) × 35 cycles, 95°C × 1 min, 55°C × 1 min) was
performed on a CFX Connect Real Time PCR Detection System (Bio-Rad, Hercules,
CA). Fold change in expression was determined by the 2ΔΔCt method. The oligonucleotide
primers (5’-3’; forward and reverse) used are shown in Table 2.1.
2.7 WESTERN BLOTTING
Whole cell lysates were prepared from sensitized human skin mast cells
(106/sample) that were activated with 100 ng/ml NP-BSA for 5 min at 37°C. Protein
equivalents of 5×105 cells/lane were separated by reducing SDS-PAGE and transferred
onto nitrocellulose membranes. Two-color staining for Akt, p38 and p42/44 was
performed using Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE), and Syk
immunoblotting was performed with 5% non-fat dry milk in 25 mM Tris, pH7.4, 0.15 M
NaCl, 0.1% Tween-20 (TNT buffer) as previously described (101). The primary
antibodies used were: rabbit polyclonal anti-p38 MAPK, mouse monoclonal antiphospho-p38 MAPK (Thr180/Tyr182)(28B10), rabbit polyclonal anti-p44/42 (Erk 1/2),
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mouse monoclonal anti-phospho-p42/44 (Erk1/2) (E10), rabbit polyclonal anti-Akt,
mouse monoclonal anti-Akt (Thr308)(L32A4), rabbit polyclonal antibody against total
Syk (Cell Signaling Technology, Danvers, MA), and mouse monoclonal antibody against
human phospho-Syk (Tyr525) (R&D Systems, Minneapolis, MN). The secondary
antibodies used were goat anti-rabbit IRDye 680RD and goat anti-mouse 800CW (LICOR Biosciences, Lincoln, NE). The blots were scanned on an Odyssey® CLx Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE).
Table 2.1: Primer sequences for qRT-PCR
Gene

Sequence

IL-6

F: AGTGAGGAACAAGCCAGAGC
R: AAAGCTGCGCAGAATGAGAT
F: GACAAGCCTGTAGCCCATGT
R: TTATCTCTCAGCTCCACGCC
F: TCTTGCTGTTCCTGCTCCTG
R: GTTGGAGCGCACTGTGAGTA
F: ACTGCTCAACACCGGAATTT
R: CAAGGGAGTCGGGCAATCAT
F: CAATGACCCCTTCATTGACC
R: TTGATTTTGGAGGGATCTCG

TNFa
COX-1
COX-2
GAPDH

2.8 STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism version 6.0c for Mac OS
X,

GraphPad

Software,

La

Jolla,
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California,

USA, www.graphpad.com.

Figure 2.1: Isolation and purification of human skin mast cells as described in Section
2.1.
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CHAPTER 3
RESULTS- RESVERATROL PREFERENTIALLY INHIBITS IGEDEPENDENT PGD2 BIOSYNTHESIS BUT ENHANCES TNF
PRODUCTION FROM HUMAN SKIN MAST CELLS2
3.1 EFFECT OF RESVERATROL ON VIABILITY OF HUMAN SKIN MAST
CELLS
To begin our studies, we sought to determine the effect of Resveratrol on viability
of human skin mast cells. Mast cells were cultured without or with 1, 10 or 100 μM
Resveratrol or DMSO for up to 72 h under normal culture conditions (37 °C, 5% CO2).
Cell viability was determined by MTT assay at each 24 h interval (Fig. 3.1). No
significant loss of viability was observed. In fact, a very slight but statistically significant
increase in cell viability was observed with Resveratrol at 10 μM for 24 h or 100 μM for
72 h compared with vehicle control. Thus, Resveratrol did not induce cell death.
3.2 PGD2 BIOSYNTHESIS IS MORE SENSITIVE THAN DEGRANULATION TO
INHIBITION BY RESVERATROL
To determine the effect of Resveratrol on degranulation, human skin mast cells
were sensitized with anti-NP IgE, pre-treated with a dose range of Resveratrol for 1 h
then challenged for 30 min with 100 ng/ml NP-BSA. Degranulation was determined by
β-hexosaminidase release assay. As shown in Fig. 3.2A, Resveratrol dose-dependently

2

Parts of this chapter have been excerpted from the following research article:

Shirley, D., C. McHale, and G. Gomez. 2016. Resveratrol preferentially inhibits IgEdependent PGD2 biosynthesis but enhances TNF production from human skin mast cells.
Biochim. Biophys. Acta - Gen. Subj. 1860.
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inhibited FcεRI-induced degranulation. Mean percent degranulation ± SEM of
control skin mast cells activated without Resveratrol was 48.5 ± 1.9% whereas that of
mast cells pre-treated with Resveratrol at the indicated concentration was: 55 ± 3% (3
μM), 52 ± 6% (6 μM), 44 ± 9% (12.5 μM), 36 ± 17% (25 μM), 20 ± 12% (50 μM) and
10.5 ± 6% (100 μM). However, significant inhibition occurred only in mast cell pretreated with Resveratrol at 50 μM (p b 0.05) and 100 μM (p b 0.0001). Thus, FcεRIinduced degranulation of human skin mast cells is resistant to inhibition with Resveratrol
at concentrations below 50 μM, but significantly inhibited with higher concentrations.
Next, we determined the effect of Resveratrol on PGD2 production. IgE-sensitized skin
mast cells were pre-treated with a dose range of Resveratrol for 1 h and then challenged
for 30 min with 100 ng/ml NP-BSA. PGD2 in the supernatant was measured with
commercial enzyme immunoassay kit. The data showed a strong inhibitory effect of
Resveratrol on PGD2 biosynthesis with significant inhibition achieved at all
concentrations tested (Fig. 3.2B). Mast cells activated without Resveratrol pretreatment
produced 27,867 ± 9099 pg/ml PGD2 whereas those pretreated with the indicated amount
of Resveratrol produced the following amount: 9306 ± 2276 pg/ml (3 μM), 5325 ± 1867
pg/ml (6 μM), 2350 ± 914 pg/ml (12.5 μM), 1165 ± 676 pg/ml (25 μM), 291 ± 259 pg/ml
(50 μM), and 31 ± 14 pg/ml (100 μM). Thus, FcεRI-induced PGD2 biosynthesis is highly
sensitive to inhibition by Resveratrol.
3.3 RESVERATROL AUGMENTS FCεRI-INDUCED TNF PRODUCTION FROM
HUMAN SKIN MAST CELLS
To evaluate the ability of Resveratrol to regulate pro-inflammatory cytokine
production, IgE-sensitized human skin mast cells were pretreated with 10 or 100 μM
Resveratrol or DMSO for 1 h, and then challenged for 3 h with 100 ng/ml NP-BSA.
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Secreted IL-6 and TNF was measured using ELISA, and cytokine gene expression was
determined by quantitative RT-PCR. Surprisingly, TNF production from mast cells
pretreated with 10 μM Resveratrol was significantly increased compared to that secreted
from untreated mast cells (Fig. 3.3A). Net TNF produced by control mast cells was 104 ±
31 pg/106 cells whereas mast cells pre-treated with 10 μM Resveratrol produced 279 ±
66 pg/106 cells. In accordance with increased TNF secretion, FcεRI-induced expression
of TNF mRNA in Resveratrol-treated mast cells was increased 2-fold compared to nontreated activated mast cells: 5 ± 1 fold increase (non-treated) versus 10 ± 2 fold increase
(Resveratrol treated) (Fig. 3.3B). In contrast, IL-6 production was not significantly
affected by 10 μM Resveratrol although some inhibition was apparent (Fig. 3.3C and D).
Thus, the enhancing effect of 10 μM Resveratrol on TNF did not extend to IL-6. At 100
μM, Resveratrol strongly inhibited IL-6 production and secretion (Fig. 3.3C and D), but
did not significantly affect TNF (Fig. 3.3A and B). In time course experiments, 10 μM
Resveratrol enhanced FcεRI-induced TNF production at 3, 6 and 24 h (Fig. 3.3F),
whereas IL-6 was inhibited at 24 h (Fig. 3.3G).We also measured β-hexosaminidase
activity in the sample supernatants to show that 10 μM Resveratrol had no effect on
degranulation even with prolonged exposure, whereas 100 μM Resveratrol completely
inhibited degranulation (Fig. 3.3E). Thus, confirming our earlier finding (Fig. 3.2A).
These data reveal a previously unrecognized ability of Resveratrol at low concentration to
enhance FcεRI-induced TNF production from human skin mast cells.
3.4 RESVERATROL INHIBITS IGE-DEPENDENT COX-2 INDUCTION BUT
NOT SYK PHOSPHORYLATION
The finding that PGD2 biosynthesis was inhibited by Resveratrol at concentrations
that did not affect degranulation (Fig. 3.2) suggested that Resveratrol at relatively low
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concentrations preferentially inhibited the eicosanoid pathway downstream of FcεRIproximal signaling events. To determine if this was the case, we first investigated the
effect of Resveratrol on expression of the cyclooxygenases COX-1 and COX-2, key
enzymes involved in the conversion of arachidonic acid to prostaglandins (34, 102). Both
COX-1 and COX-2 are involved in PGD2 biosynthesis. However, whereas COX-1 is
constitutively expressed in mast cells, COX-2 expression is an inducible event following
FcεRI stimulation. In fact, COX-2 is the only major enzyme involved in eicosanoid
production whose expression is induced in mast cells following FcεRI crosslinking; thus,
making it an ideal candidate target for Resveratrol. To this end, IgE-sensitized skin mast
cells were pre-treated with 1, 10 or 100 μM Resveratrol or DMSO for 1 h, and then
challenged for 30 min with 100 ng/ml NP-BSA. Total RNA was isolated, and COX-1 and
COX-2 expression was assessed by real time PCR. As expected, COX-1 expression was
not affected whereas COX-2 expression was significantly increased after FcεRI
crosslinking. Moreover, pre-treatment with Resveratrol had no effect on the constitutive
expression of COX-1 (Fig. 3.4A), whereas IgE-dependent COX-2 expression was
significantly inhibited in skin mast cells pre-treated with 10 μM (p b 0.05) or 100 μM
Resveratrol (p b 0.01) (Fig. 3.4B). The fold increase ± SEM in COX-2 expression in
FcεRI-activated control mast cells was 29 ± 5, and 36 ± 5, 17 ± 4, or 1 ± 0.2,
respectively, in mast cells pre-treated with 1, 10 or 100 μM Resveratrol. Interestingly,
COX-2 expression appeared to be slightly increased in skin mast cells pre-treated with 1
μM Resveratrol although the difference was not statistically significant (p = 0.2). Thus,
FcεRI induced COX-2 expression was significantly inhibited by Resveratrol. Our finding
that high concentrations of Resveratrol were required to inhibit degranulation indicated
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that FcεRI-induced signals occurred normally with Resveratrol at low concentrations. To
confirm this, we analyzed the effect of Resveratrol on Syk activation since degranulation
is dependent on Syk activation (103–105). Upon FcεRI crosslinking, Syk is rapidly
recruited to ITAM residues on FcεRI γ chains where it is phosphorylated to propagate the
cascade of signaling events (106). Therefore, we analyzed the phosphorylation status of
Syk at the activating tyrosine residue Y525 by SDS-PAGE and Western blotting. Whole
cell lysates were prepared from IgE-sensitized human skin mast cells that had been
pretreated with 1, 10 or 100 μM Resveratrol or DMSO for 1 h and then activated for 5
min with 100 ng/ml NP-BSA. As expected, phosphorylated Syk was clearly detected in
lysates from FcεRI-activated mast cells, but not in non-activated mast cells. Further,
FcεRI-induced Syk phosphorylation was not affected in skin mast cells pre-treated with 1
or 10 μM Resveratrol (Fig. 3.5) in accordance with the observation that Resveratrol at
these concentrations did not affect degranulation (Fig. 3.2A), which is dependent on Syk
activation (104). Interestingly, Resveratrol at 100 μM, a concentration that completely
inhibited degranulation (Fig. 3.2A), also did not significantly inhibit FcεRI-induced Syk
phosphorylation (17 ± 5% versus 28 ± 6% in control cells; p = 0.2) although an inhibitory
trend was apparent. Thus, FcεRI-induced Syk phosphorylation was not inhibited with
Resveratrol in human skin mast cells.
3.5 INCREASED TNF PRODUCTION BY RESVERATROL IS NOT DUE TO
INCREASED FCεRI-INDUCED ACTIVATION OF AKT, P38, OR P42/44
To determine the effect of Resveratrol on downstream signaling processes, we
analyzed the phosphorylation status of Akt, p38 and p42/44 (ERK1/2) following FcεRI
cross-linking since these intermediate signaling molecules have been implicated in
activation of various transcription factors and cytokine production by mast cells (107–
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109). To do so, SDS-PAGE and Western blotting were performed using whole cell
lysates prepared from IgE-sensitized human skin mast cells that were pre-treated with
Resveratrol at 1, 10 or 100 μM for 1 h, and challenged for 5 min with 100 ng/ml NPBSA. As demonstrated in Fig. 3.6, FcεRIinduced phosphorylation of Akt was minimally
inhibited with 10 μM Resveratrol whereas p38 or p42/44 phosphorylation was not
affected. In contrast, 100 μM Resveratrol completely inhibited the phosphorylation of
these signaling molecules. These data indicate that the observed increase in TNF
production from human skin mast cells pre-treated with 10 μM Resveratrol (Fig. 3.3) was
not due to an increase in FcεRI-induced activation of Akt, p38 or p42/44.
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Figure 3.1: Effect of Resveratrol on viability of human skin mast cells. Human skin mast
cells were treated with 1, 10 or 100 μM Resveratrol or DMSO for 24, 48, or 72 h, and cell
viability was determined by MTT reduction assay as described in Material and methods.
Absorbance values at 570 nm correspond to cell viability. Bars represent the
mean ± SEM (n = 3) of absorbance values obtained with mast cells isolated from normal
skin tissue of different donors. *p < 0.05 by Student's t-test comparing absorbance values
from vehicle-treated cells to those treated with Resveratrol.
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Figure 3.2: Effect of Resveratrol on FcεRI-induced degranulation and PGD2 production
from human skin mast cells. Dose-dependent effect of Resveratrol on Ag/IgE-induced
degranulation (A) or PGD2 production (B) from human skin mast cells sensitized with
chimeric human anti-NP IgE and challenged with 100 ng/ml NP-BSA. Percent
degranulation was determined by β-hexosaminidase release assay. Calcium ionophore
A23187 was used as a positive control for degranulation potential. Secreted PGD2 was
measured by enzyme immunoassay. Data are expressed as the mean ± SEM of values
obtained from independent experiments with mast cells from normal skin tissue of n = 3
(A, degranulation) or n = 5 (B, PGD2) different donors. Values were compared to those
obtained from mast cells that were activated without Resveratrol (NP-BSA only).
Statistical significance was determined by one-way ANOVA followed by Dunnett's
multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, and #p < 0.0001.
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Figure 3.3: Effect of Resveratrol on FcεRI-induced production of TNF and IL-6 from
human skin mast cells. Human skin mast cells sensitized with anti-NP IgE were pretreated with Resveratrol for 1 h and then challenged with antigen NP-BSA for 3 h (A–E),
or 3, 6, or 24 h (F and G). Secreted cytokines in supernatant were measured by ELISA,
and gene expression was assessed by quantitative RT-PCR. Fold change was determined
by 2ΔΔCt method comparing to expression in non-activated mast cells (y = 1, hatched
line). Net secreted TNF (A, n = 6) or IL-6 (C, n = 5). Spontaneously released TNF was
8 ± 4 pg/106 cells, and IL-6 was 2 ± 2 pg/106 cells. Fold change in TNF (B, n = 7) or IL-6
(D, n = 7) gene expression. β-Hexosaminidase in media (E, n = 6). Time course
evaluation for TNF (F, n = 3) or IL-6 (G, n = 3). Data shown is expressed as
mean ± SEM of values from skin mast cells from different donor tissue in independent
experiments. Statistical significance was determined by one-way ANOVA followed by
Sidak's multiple comparisons test. *p < 0.5, ***p < 0.001, and #p < 0.0001.
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Figure 3.4: Effect of Resveratrol on COX-1 and COX-2 expression in human skin mast
cells. Expression analysis of COX-1 (A, n = 6) or COX-2 (B, n = 5) in FcεRI-activated
humans was performed by qRT-PCR in independent experiments with mast cells from
different donor tissue. Fold change, expressed as mean ± SEM, was determined by
2ΔΔCt method comparing to expression in non-activated mast cells (y = 1, hatched line).
The data reflect the effect of Resveratrol on the constitutive expression of COX-1 and
induction of COX-2. Statistical significance was determined by pairwise Student's t-test
comparing to values from mast cells activated without Resveratrol pre-treatment.
*p < 0.05 and **p < 0.01.
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Figure 3.5: Effect of Resveratrol on FcεRI-induced phosphorylation of Syk in human skin
mast cells. Phosphorylation of Syk (Y525) was determined by quantitative infrared
Western blotting of whole cell lysates of sensitized mast cells pre-treated with 1, 10 or
100 μM Resveratrol or DMSO (vehicle), and activated for 5 min with 100 ng/ml NPBSA. The blot shown (A) is representative of 3 independent experiments with mast cells
from skin tissue of different donors. Percent phosphorylation expressed as mean ± SEM
(B, n = 3) was determined as the ratio of phosphorylated Syk (Y525) to total Syk using
fluorescent signal values obtained with an infrared imager. Statistical significance was
determined by Student's t-test comparing to values from mast cells activated without
Resveratrol pre-treatment. *p < 0.05.
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Figure 3.6: Effect of Resveratrol on FcεRI-induced phosphorylation of Akt, p42/44 and
p38 in human skin mast cells. Phosphorylation of Akt (A), p42/44 (B, upper panel) and
p38 (B, lower panel) was determined by quantitative infrared Western blotting of whole
cell lysates of sensitized mast cells pre-treated with 1, 10 or 100 μM Resveratrol or
DMSO (vehicle), and activated for 5 min with 100 ng/ml NP-BSA. Fold induction of
phosphorylation was determined from fluorescent signal values obtained with an infrared
imager. The blots shown are representative of 3 independent experiments with mast cells
from skin tissue of different donor.
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CHAPTER 4
DISCUSSION- RESVERATROL PREFERENTIALLY INHIBITS IGEDEPENDENT PGD2 BIOSYNTHESIS BUT ENHANCES TNF
PRODUCTION FROM HUMAN SKIN MAST CELLS3
In this study, we investigated the effects of Resveratrol on IgE-dependent release
of allergic and inflammatory mediators from mast cells that were isolated and purified
from human skin tissue. Studies have shown that Resveratrol can inhibit mediator release
from mouse mast cells (47, 50, 110). However, there are currently no studies showing the
direct effect of Resveratrol on human mature mast cells, and the mechanism or target of
Resveratrol has not been identified. Here, we identified the COX-2 pathway leading to
PGD2 biosynthesis as a target for inhibition by Resveratrol at low concentrations. In
addition, we uncover the ability of Resveratrol to enhance the production of TNF from
human skin mast cells, a previously unrecognized pro-inflammatory effect.
The finding that Resveratrol preferentially inhibited PGD2 production was
corroborated by the observation that FcεRI-induced COX-2 expression but not Syk
phosphorylation was inhibited by Resveratrol. In fact, Resveratrol failed to inhibit Syk
phosphorylation even at an extremely high concentration (100 μM) that completely
blocked downstream Akt, p38 or p42/44 phosphorylation. These findings provide the first
evidence of preferential or selective inhibition of mediator release from human mature

3

Parts of this chapter have been excerpted from the following research article:
Shirley, D., C. McHale, and G. Gomez. 2016. Resveratrol preferentially inhibits IgE-dependent
PGD2 biosynthesis but enhances TNF production from human skin mast cells. Biochim. Biophys.
Acta - Gen. Subj. 1860.
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mast cells by Resveratrol at concentrations more likely to be achieved
physiologically. In addition, these data demonstrate that FcεRI-proximal Syk is not a
target of Resveratrol. Interestingly, Resveratrol is a non-hydroxylated analog of naturally
occurring piceatannol (3, 3′, 4, 5′-trans-trihydroxystilbene), a widely used inhibitor of
Syk (111). The finding that FcεRI-induced COX-2 expression was inhibited with a
relatively low concentration of Resveratrol, while phosphorylation of receptor-proximal
Syk or downstream signaling molecules Akt, p38 or p42/44 was not, indicates that
Resveratrol selectively targeted the FcεRI-induced eicosanoid biosynthesis pathway to
inhibit PGD2 production. These data suggest that Resveratrol as a therapeutic agent might
protect against allergic effects mediated by PGD2 but not against pre-formed mediators
like histamine, which are stored in cytoplasmic granules and released during
degranulation.
Our data showing that Resveratrol at a relatively low concentration (10 μM)
enhanced rather than inhibited TNF production was surprising given its reported antiinflammatory properties. Resveratrol and other polyphenols have been shown to inhibit
TNF and other cytokines from human mast cells. One study demonstrated that
Resveratrol (10 or 50 μM) inhibited cytokine production from the human mast cell line
HMC-1 following stimulation with phorbol ester (PMA) + ionomycin (51). However, one
critical difference from our study is that HMC-1 cells do not express FcεRI (112), and,
thus, cannot be stimulated by IgE/Ag. Therefore, the signaling pathway(s) induced in
HMC-1 transformed cells by PMA + ionomycin are likely distinct from those initiated by
FcεRI crosslinking in normal primary mast cells used in our study. The flavones, luteolin,
quercetin, and baicalein (1–100 μM) have also been shown to inhibit TNF and other
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cytokines from human cultured mast cells, mast cell lines, or mouse BMMCs (113–116).
Recently, the novel flavone tetramethoxyluteolin (methlut; 1–100 μM), a structural
analog of luteolin, was shown to potently inhibit TNF production from IgE/anti-IgEactivated human cord blood-derived mast cells or the LAD2 mast cell line (44). Our
finding is supported by a recent study demonstrating an increase in plasma TNF levels in
healthy subjects given oral Resveratrol (5 g), and in vitro (10 or 30 μM) from LPSstimulated human peripheral blood mononuclear cells or monocytes pre-treated with
Resveratrol (117). Despite the numerous studies performed in mice or with mouse mast
cells, there are no reported pro-inflammatory effects of Resveratrol or other polyphenols
on allergic responses. Our finding and that of Gualdoni et al. are the first proinflammatory effects of Resveratrol on human primary immune cells to be reported.
Therefore, the possibility exists that Resveratrol has different effects on human and
mouse mast cells that have yet to be fully elucidated with regard to IgE-dependent
responses. It is not currently known if the potentiating effect is specific to MCTC type
mast cells in skin or if TNF production from MCT mast cells in lung is also enhanced.
Nevertheless, it appears that in addition to its well-documented anti-inflammatory
properties, Resveratrol has pro-inflammatory effects in humans that could dampen its
potentially healthful benefits for which it has garnered intense interest.
On the other hand, since Resveratrol is known to inhibit inflammation, it is
possible that the increased amount of TNF induced by Resveratrol specifically from
human skin mast cells is negated by Resveratrol's overall anti-inflammatory properties.
The observed increase in TNF reported here could also represent a localized response to
Resveratrol in human skin particularly with regard to allergic inflammation. If so, this
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raises the issue of whether the overall physiological effect of Resveratrol is dependent on
the route of delivery. This is particularly intriguing given that different methodologies to
enhance the efficiency of topical administration of Resveratrol are currently being
developed to deliver the polyphenol (118–122). Clearly, issues regarding route of
delivery, solubility, and bioavailability will ultimately determine the efficacy of using
Resveratrol or other polyphenols with limited solubility as therapeutic agents.
The mechanism by which Resveratrol enhances TNF production from human skin
mast cells is not known. However, an effect on the NF-κB pathway is suspected since
NF-κB is required for IgE-dependent TNF production from mast cells (123). Indeed,
enhanced TNF production by Resveratrol from LPS-stimulated human monocytes was
associated with increased phosphorylation of p105, a component of the alternative
pathway for NF-κB activation (45) suggesting that increased TNF production by
Resveratrol could be due to increased NF-κB transcriptional activity. However,
Resveratrol or other polyphenols were shown to inhibit NF-κB activation in human
cultured mast cells, LAD2 or HMC-1 mast cell lines, or various transformed cell lines
including U937, Jurkat, HeLa (51, 124, 125). One critical question that needs to be
addressed is: If NF-κB activation is involved in Resveratrol-induced enhancement of
TNF production, how do we reconcile this with the observations that NF-κB is inhibited
with Resveratrol? To answer this, additional studies are needed to determine the effect of
Resveratrol on canonical and non-canonical NF-κB activation in human mature mast
cells. Nevertheless, our finding that FcεRI-induced phosphorylation of p38 or p42/44,
which are involved in cytokine production from FcεRI-activated mast cells, was not
altered with Resveratrol at a concentration that enhanced TNF production suggests a
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target further downstream in the FcεRI pathway possibly NF-κB or other transcription
factor(s).
Resveratrol isomerization is known to be induced by the activation energy of solar
or ultraviolet radiation (i.e. light) (126). Trans-Resveratrol is believed to be the primary
and most stable natural form of this stilbene, and this isomer is associated with the
multitude of Resveratrol’s reported biomedical health benefits (127). Additionally, transResveratrol is believed to be non-toxic while less is known about the safety of the cisisomer (126). For this reason, the present study involved the treatment of human skin
mast cells with trans-Resveratrol. However, we failed to examine the isomerization of
Resveratrol at the concentrations used, and so cannot be fully confident that the effects
reported in this study are solely a product of trans-Resveratrol. In the future, nuclear
magnetic resonance (NMR) should be employed to determine the isomerization of
Resveratrol at low concentrations.
Our study corroborates previous reports showing that high concentrations of
Resveratrol inhibited mast cell degranulation and cytokine production. Here we show that
Resveratrol at 100 μM strongly inhibited degranulation, PGD2 and cytokine production.
However, whether the inhibitory effect with high concentrations of Resveratrol is
physiologically relevant is questionable. It is unknown if human skin can absorb 50–
100 μM Resveratrol, the concentration range required to significantly inhibit
degranulation, via topical application, but such high concentrations are unlikely to be
achieved in tissues at least via oral route (128). Moreover, our data demonstrates that
Resveratrol did not induce a loss in viability of human skin mast cells even at high
concentrations indicating that the inhibitory effect was not due to cell toxicity.
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Overall, we demonstrate that Resveratrol at relatively low concentrations: (1)
preferentially inhibits the COX-2 pathway leading to PGD2 production; and (2) enhances
TNF production from FcεRI-activated human skin mast cells. Together, these findings
suggest that Resveratrol as a potential treatment for allergic reactions would be mostly
effective against arachidonic acid-derived lipid mediators rather than histamine, but could
also exacerbate or promote mast cell-mediated allergic inflammation in the skin.
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CHAPTER 5
MATERIALS AND METHODS- INTERLEUKIN-6 POTENTIATES
FCΕRI-INDUCED PGD2 BIOSYNTHESIS AND INDUCES VEGF FROM
HUMAN IN-SITU-MATURED SKIN MAST CELLS4
Interleukin-6 (IL-6) is a classical pro-inflammatory cytokine ubiquitously
associated with pathological inflammation. In humans, IL-6 levels are correlated with
severity or pathogenesis of allergic diseases including asthma, urticaria, and
mastocytosis. The true role of IL-6 in allergic disease remains poorly understood, with
particular reference to how it modulates mast cell function. Mast cells are capable of
producing robust amounts of IL-6 when activated, but it had not been previously shown if
mature in-situ-derived human skin mast cells were responsive to IL-6 signaling. The
methods described in this section were designed to identify the presence of the
membrane-bound IL-6 receptor on the surface of human skin mast cells and assess the
function consequences of its signaling on inflammatory mediator production. Studies
were performed on in-situ-matured human skin mast cells isolated in accordance with the
University of South Carolina Internal Review Board (IRB).
5.1 ISOLATION, PURIFICATION, AND CULTURE OF HUMAN SKIN MAST
CELLS
As described in Section 2.1.

4

Parts of this chapter have been excerpted from the following research article:
McHale, C., Z. Mohammed, J. Deppen, and G. Gomez. 2018. Interleukin-6 potentiates FcεRIinduced PGD2 biosynthesis and induces VEGF from human in situ-matured skin mast cells.
Biochim. Biophys. Acta - Gen. Subj. 1862.
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5.2 IGE SENSITIZATION AND FCΕRI CROSSLINKING
Mast cells (106 cells/ml) were incubated in X-VIVO 15™ media containing SCF
(100 ng/ml) and 1 μg/ml chimeric human anti-NP IgE (human Fc + mouse Fab) (clone
JW8/1)(AbD Serotec, Raleigh, NC) overnight at 37oC, 5% CO2.

After washing to

remove unbound IgE, the mast cells were re-suspended at 106 cells/ml in X-VIVO 15™
media or Tyrode’s buffer (135 mM NaCl, 1 mM MgCl2, 20 mM Hepes, 5 mM KCl, 1.8
mM CaCl2, 5.6 mM glucose; pH 7.4, 0.05% bovine serum albumin), and activated with
the hapten 4-hydroxy-3-nitrophenylacetyl conjugated to bovine serum albumin at a 16:1
molar ratio (NP-BSA; Biosearch Technologies, Novato, CA) at the indicated
concentration at 37oC for the indicated amount of time.
5.3 PGD2 AND DEGRANULATION ASSAYS
Degranulation was measured by β-Hexosaminidase release assay.

After

sensitization with anti-NP IgE, the mast cells were washed and resuspended at 106
cells/ml in Tyrode’s buffer, pre-treated as describe in figure legends, and activated with
NP-BSA for 30 min. After the activation period, mast cells and buffer were separated by
centrifugation (2000 rpm × 5 min), and the pelleted cells were lysed with an equal
volume of 1% Triton X-100. β-Hexosaminidase activity in supernatant and cell lysate
was determined by the release of p-nitrophenol from substrate p-nitrophenyl N-acetyl-βD-glucosaminide (pNAG; Sigma-Aldrich, St. Louis, MO) as described (98, 99). In a 96well plate, 5 μl of supernatant or lysate were mixed with 45 μl of 4mM p-Nitrophenyl Nacetyl-β-D-Glucosaminide (pNAG) in citric acid buffer (pH 4.5) and incubated for 1 h at
37oC. The reaction was stopped with 150 μl of 0.2 M glycine, pH 10.7. Absorbance
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values at 405 nm were acquired with a BioTek Synergy HT microplate reader (BioTek,
Winooski, VT). Percent β-hexosaminidase release was calculated from the absorbance
values

according

to

the

formula:

%

β-hexosaminidase

release

=

((supernatant)/(supernatant + lysate)) × 100. PGD2 in the supernatants was measured by
commercial assay (Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s
protocol.
5.4 QUANTITATIVE REAL TIME PCR
Gene expression was determined by quantitative real time PCR.

RNA was

isolated with the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was synthesized from
total RNA with iScript cDNA Synthesis kit and PCR was performed using iQ SYBR®
Green Supermix (Bio-Rad, Hercules, CA). The kits were used according to the
manufacturer’s instructions. The PCR reaction mix was composed of 2 μl of cDNA, 1 μl
each of sense and antisense primers (10 μM each) and 12.5 μl of iQ SYBR® Green
Supermix in a final volume of 25 μl. A hot-start PCR protocol (95°C × 5 min, (95°C × 30
sec, 55°C × 30 sec, 72°C × 30 sec) x 35 cycles, 95°C × 1 min, 55°C × 1 min) was
performed on a CFX Connect Real Time PCR Detection System (Bio-Rad, Hercules,
CA).

Fold change in expression was determined by the 2ΔΔCt method with β2

microglobulin (B2M) as the reference gene. The oligonucleotide primers used were (5’3’; forward and reverse) are shown in Table 5.1.
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Table 5.1: Primer sequences used for qRT-PCR.
Gene

Sequence

VEGF

F: CCATGCAGATTATGCGGATCAAA
R: CACCAACGTACACGCTCCAG
F: GCTCCAAGAGCGAGTACCAG
R: CTGTCGCGGATCAGAAAGGT
F: TCT GGGAGTGCTGTTCTGCTT
R: TGTGCCTTGGAGGAGTGTGA
F: CTCATCTTTCTACAGACTACG
R: GACCATCCATGTTGTGAATG
F: TCTTGCTGTTCCTGCTCCTG
R: GTTGGAGCGCACTGTGAGTA
F: ACTGCTCAACACCGGAATTT
R: CAAGGGAGTCGGGCAATCAT
F: TGGGTTTCATCCATCCGACA
R: CTGCTTACATGTCTCGATCCC

SOCS3
gp130
IL-6Ra
COX-1
COX-2
B2M

5.5 WESTERN BLOTTING
106 mast cells were lysed with 0.1 ml Tris-Glycine SDS Sample Buffer (Life
Technologies, Carlsbad, CA) containing 1% β-mercaptoethanol and 1 mM Na3VO4.
Protein equivalents of 5x105 cells/lane were separated by SDS-PAGE, and then
transferred onto nitrocellulose membranes. After transfer, the membranes were blocked
for 1 h at room temperature with Odyssey Blocking Buffer (LI-COR Biosciences,
Lincoln, NE). Two-color staining for total and phosphorylated STAT3 was performed
with the primary antibodies Stat3 (79D7) rabbit mAb and phospho-STAT3
(Tyr705)(3E2) mouse mAb or phospho-STAT3 (Ser727)(6E4) mouse mAb (Cell
Signaling Technology, Danvers, MA), and secondary antibodies goat anti-rabbit IRDye
680RD and goat anti-mouse 800CW (LI-COR Biosciences, Lincoln, NE). The blots
were incubated overnight at 4oC with primary antibodies, and for 1 h at room temperature
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with secondary antibodies.

The blots were scanned on an Odyssey® CLx Infrared

Imaging System (LI-COR Biosciences, Lincoln, NE).
5.6 FLOW CYTOMETRY
Human skin mast cells (106) were washed with FACS buffer (1% BSA, 0.04%
NaN3 in PBS), and Fc receptors were blocked with Human TruStain FcX™ (5 µl/106
cells) (BioLegend, San Diego, CA) and 1% normal human serum for 15 min on ice to
prevent non-specific binding. The mast cells were then stained with PE-labeled antihuman CD130 (gp130) (clone 2E1B02), CD126 (IL-6Rα) (clone UV4), FcεRIα (clone
AER-37 (CRA-1)), or respective isotype control, mouse IgG2a,k, IgG1,k, IgG2b,k
(BioLegend, San Diego, CA) for 1 h on ice. After washing twice, the mast cells were resuspended in 200 µl FACS buffer and run on a Beckman Coulter Cytomics FC500. Data
was analyzed with FlowJo software (FlowJo LLC, Ashland, OR).
5.7 CYTOKINE MEASUREMENTS
Mast cells (106 cells/ml) were sensitized with anti-NP IgE, pre-treated or not with
IL-6 as indicated, and activated with NP-BSA for 24 h at 37oC in X-VIVO 15™ media
containing SCF (100 ng/ml) and soybean trypsin inhibitor (100 μg/ml) (SBTI; SigmaAldrich, St. Louis, MO).

After the activation period, mast cells and media were

separated by centrifugation (2000 rpm x 5 min), and secreted cytokines in supernatant
were measured by enzyme-linked immunosorbent assay (ELISA). VEGF was measured
using commercial kits (R&D Systems, Minneapolis, MN) according to the
manufacturer’s protocol. TNF and IL-8 were measured using capture (purified) and
detection (biotinylated) rat antibodies, and serially diluted recombinant cytokine
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standards for standard curves (BD Biosciences, San Jose, CA) in a 384-well format as
described (100). The plates were developed with the substrate peroxidase 2,2’-azino-bis3-ethylbenzthiazoline-6-sulfonic

acid

(ABTS;

Sigma-Aldrich,

St.

Louis,

MO).

Absorbance values at 405 nm were obtained with a BioTek Synergy HT microplate
reader (BioTek, Winooski, VT), and cytokine concentrations determined using Gen5
Data Analysis Software.
5.8 STATISTICAL ANALYSIS
As described in Section 2.8.
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CHAPTER 6
RESULTS- INTERLEUKIN-6 POTENTIATES FCΕRI-INDUCED PGD2
BIOSYNTHESIS AND INDUCES VEGF FROM HUMAN IN-SITUMATURED SKIN MAST CELLS 5
6.1 HUMAN SKIN MAST CELLS CONSTITUTIVELY EXPRESS MEMBRANEBOUND GP130 AND IL-6RΑ
The IL-6 receptor is comprised of gp130 and IL-6Rα subunits. Gp130 is a
membrane bound protein whereas IL-6Rα exists as membrane-bound and secreted forms.
Both gp130 and IL-6Rα have been shown expressed on in vitro-derived mast cells (70,
73), but their expression on human in situ-matured mast cells had not been reported.
Here, we demonstrate by flow cytometry that human skin mast cells constitutively
express gp130 (Figure 6.1A) and membrane-bound IL-6Rα (Figure 6.1C) on their
surface. Net Mean Fluorescence Intensity (MFI) of gp130 staining was 778 ± 89
compared to 204 ± 9 for IgG isotype control (n=3, p=0.003) (Figure 6.1B), and of IL-6Rα
staining was 937±37 compared to 722.5 ± 7.5 for IgG isotype control (n=3, p=0.03)
(Figure 6.1D). Because mouse bone marrow-derived mast cells (BMMCs) reportedly
require IL-10 for gp130 expression (129), we determined the effect of IL-10 on gp130
expression on human skin mast cells. Interestingly, treatment with IL-10 (10 ng/ml) for
24 h resulted in a significant increase in gp130 mRNA expression (3.5 ± 0.7 fold change,
n=3, p=0.02) (Figure 6.1E), but did not enhance the surface expression of gp130 (Figure
5

Parts of this chapter have been excerpted from the following research article:
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6.1F). Thus, primary in situ-matured mast cells from human skin constitutively
express gp130 and membrane bound IL-6Rα.
6.2 HUMAN SKIN MAST CELLS EXPRESS FUNCTIONAL MEMBRANE
BOUND RECEPTORS FOR IL-6 CAPABLE OF TRANSMITTING POTENT IL6-INDUCED SIGNALS VIA CLASSICAL SIGNALING
The constitutive expression of gp130 and membrane bound IL-6Rα on human
skin mast cells suggested that these cells could be directly stimulated by IL-6 via classical
signaling. To determine if gp130 and IL-6Rα subunits formed functional signaling
complexes, we analyzed the phosphorylation status of Signal Transducer and Activator of
Transcription 3 (STAT3), a known target of gp130 signals that is implicated in mast cell
degranulation and anaphylaxis reactions (130–132), in human skin mast cells stimulated
with IL-6. As demonstrated with Western blot, stimulation of human skin mast cells for
15 minutes with 1, 10 or 100 ng/ml of recombinant IL-6 induced a dose-dependent
increase in STAT3 phosphorylation (Figure 6.2A, left side).

For comparison, we

stimulated skin mast cells in parallel with IL-27, which also utilizes gp130 and has been
implicated in the regulation of mast cells and human allergic disease (133–136). As
expected, IL-27 induced STAT3 phosphorylation (Figure 6.2A, right side). However,
STAT3 phosphorylation induced with IL-6 was significantly and dramatically greater
than that induced by IL-27 (Figure 6.2B); thus, demonstrating the potency of IL-6
induced gp130 signals. Next, we analyzed the expression of Suppressor of Cytokine
Signaling 3 (SOCS3), a downstream target of STAT3, in human skin mast cells
stimulated with IL-6 or IL-27. In time-course experiments, SOCS3 mRNA expression
was rapidly induced, peaking within 1h of treatment with 100 ng/ml of IL-6 (Figure
6.2C) or IL-27 (Figure 6.2D).

Reflective of the difference in intensity of STAT3
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phosphorylation induced by IL-6 or IL-27, the IL-6-induced increase in SOCS3 mRNA
was dramatically greater than that induced with IL-27 at 1 h post-treatment (362 ± 128
versus 9 ± 0.3). By 3 h post-treatment, the SOCS3 mRNA level in IL-27-treated mast
cells had returned to baseline levels, and in IL-6-treated mast cells was considerably
reduced with continued temporal regression.

Thus, human skin mast cells express

functional membrane-bound IL-6 receptors capable of transmitting highly potent gp130
signals via direct stimulation with IL-6 (classical signaling).
6.3 IL-6 HAS NO EFFECT ON FCΕRI-INDUCED DEGRANULATION OF
HUMAN SKIN MAST CELLS
IL-6 was recently shown to enhance the degranulation of in vitro-derived CBMCs
(73). Therefore, given the association between severity of allergic disease and IL-6 in
humans, we sought to determine the effect of IL-6 on FcεRI-induced degranulation of
human in situ-matured mast cells. Human skin mast cells were sensitized with chimeric
human anti-NP IgE, pre-treated with 1, 10 or 100 ng/ml of recombinant human IL-6 for 1
h, and then challenged with NP-BSA (100 ng/ml) for 30 min.

Degranulation was

determined by β-hexosaminidase assay. As demonstrated, IL-6 had no effect on FcεRIinduced degranulation of human skin mast cells (Figure 6.3A). In the converse set of
experiments, IgE-sensitized human skin mast cells were pre-treated or not with IL-6 at a
high concentration (100 ng/ml), and then challenged with 0.1, 1, 10, or 100 ng/ml of NPBSA. As shown, IL-6 at failed to enhance degranulation induced with a dose range of
NP-BSA representing sub-maximal to maximal levels of FcεRI crosslinking (Figure
6.3B). Noteworthy, IL-6 failed to enhance degranulation of human skin mast cells even
at a concentration (100 ng/ml) that strongly induced the phosphorylation STAT3 (Figure
6.2A), which has itself been implicated in mast cell degranulation (130–132). Since
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human MCTC mast cells are known to spontaneously secrete IL-6 (Figure 6. 3C) (71), and
prolonged exposure to IL-6 was reported to enhance degranulation of in vitro-derived
cord blood-derived mast cells (CBMCs) (73), we sought to determine if the potential or
capacity of skin mast cells for degranulation was somehow affected by endogenous IL-6.
To address this, we cultured human skin mast cells with neutralizing anti-IL-6 antibody
(1 μg/ml) or isotype control for up to 3 days, and measured FcεRI-induced degranulation
at daily intervals. As shown, β-hexosaminidase release from mast cells cultured with
neutralizing anti-IL-6 antibody was nearly identical to that from mast cells cultured with
non-specific IgG control or media alone at each time-point (Figure 6.3D). Thus, gp130
signaling initiated by exogenous IL-6 does not enhance or inhibit FcεRI-induced
degranulation of human skin mast cells. Moreover, long term exposure to endogenously
produced IL-6 does not appear to influence the capacity or potential of human skin mast
cells for degranulation.
6.4 IL-6 POTENTIATES FCΕRI-INDUCED PGD2 BIOSYNTHESIS
Mast cells are major producers of PGD2 (34), a critical component of allergic
airways inflammation (39). Since IL-6 had no effect on mast cell degranulation, we
sought to determine the effect on FcεRI-induced PGD2 biosynthesis. To do so, IgEsensitized human skin mast cells were pre-treated with 1, 10, or 100 ng/ml of IL-6 for 1
h, and then challenged with NP-BSA (100 ng/ml) for 30 min. PGD2 in cell-free media
was quantified by enzyme immunoassay.

As shown, IL-6 significantly and dose-

dependently enhanced the amount of PGD2 secreted from FcεRI-activated human skin
mast cells (Figure 6.4A). In the converse set of experiments, IgE-sensitized human skin
mast cells were pre-treated or not with IL-6 (100 ng/ml) and then challenged with 0.1, 1,
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10, or 100 ng/ml of NP-BSA. As shown, mast cells treated with IL-6 produced more
PGD2 than control mast cells with significant differences detected with NP-BSA at 10
ng/ml or 100 ng/ml (Figure 6.4B).

Thus, IL-6 potentiates FcεRI-induced PGD2

biosynthesis from human skin mast cells.
6.5 IL-6 ENHANCES FCΕRI-INDUCED COX-2 EXPRESSION AND PGD2
PRODUCTION BY A STAT3-DEPENDENT MECHANISM
To begin to understand the mechanism, we analyzed the effect of IL-6 on
expression of COX-1 and COX-2, key enzymes in the eicosanoid pathway leading to
prostaglandin biosynthesis (102). Human skin mast cells were sensitized with anti-NP
IgE, pretreated with 100 ng/ml or a dose range of 1 – 100 ng/ml of IL-6 for 1 h, and then
activated with NP-BSA (100 ng/ml) for 1 h. Changes in expression of COX-1 and COX2 were determined by quantitative real time PCR. As expected since COX-2 is an
inducible enzyme whereas COX-1 is constitutively expressed, the expression of COX-2,
but not COX-1, was induced with FcεRI crosslinking (Figure 6.5A and C). In accordance
with the ability to potentiate PGD2 biosynthesis (Figure 6. 4), IL-6 significantly enhanced
the FcεRI-induced expression of COX-2 (Figure 6.5A and B). IL-6 alone had no effect
on the expression of either enzyme. Noteworthy, IL-6 had no effect on expression of
hematopoietic prostaglandin D synthase (HPGDS), which catalyzes the conversion of
prostaglandin H2 (PGH2) to PGD2 [45], or RasGRP4, which regulates HPGD2S
expression in mast cells (137) (not shown).
To confirm that the IL-6-induced increase in COX-2 and PGD2 was due to
STAT3 activation, we used the small molecule inhibitor of STAT-3 tyrosine
phosphorylation C188-9 (138). First, we determined the efficacy of C188-9 to inhibit IL-
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6-induced STAT3 phosphorylation at the activating tyrosine 705 in human skin mast
cells. In dose curve experiments, human skin mast cells were pre-treated or not with
C188-9 (6.25 to 100 μM) for 1 h, and then stimulated with IL-6 (100 ng/ml) for 15 min.
STAT3 phosphorylation was determined by Western blot analysis of whole cell lysates.
As shown, C188-9 dose-dependently inhibited the IL-6-induced phosphorylation of
STAT3 at the Y705 (Figure 6.5D). Next, we sought to determine if C188-9 would inhibit
the IL-6-induced enhancement of FcεRI-induced COX-2 expression. Human skin mast
cells were sensitized with anti-NP IgE, pre-treated with C188-9 (25 μM) for 1 h, and then
stimulated with IL-6 (100 ng/ml) for 1 h. The mast cells were then activated with NPBSA (10 ng/ml) for an additional 1 h. As demonstrated by quantitative real-time PCR,
C188-9 completely inhibited the IL-6-induced increase in COX-2 expression (Figure
6.5E). Similarly, C188-9 was shown to be highly effective at inhibiting the IL-6-induced
biosynthesis of PGD2 (Figure 6.5F). Together, these data confirm that the enhancing
effect of IL-6 on FcεRI-induced PGD2 biosynthesis and COX-2 expression was indeed
due to STAT3 activation.
6.6 IL-6 INDUCES VEGF PRODUCTION AND ENHANCES FCΕRI-INDUCED
IL-8 SECRETION.
The ability of mast cells to produce VEGF is abundantly documented (139).
Having shown that human skin mast cells express functional membrane-bound IL-6Rα
and gp130, we sought to determine if classical signaling with IL-6 could induce or
enhance FcεRI-induced VEGF production from these cells. To do so, human skin mast
cells were sensitized with anti-NP IgE, pre-treated with 1, 10, or 100 ng/ml of IL-6 for 1
h, and then challenged with NP-BSA (100 ng/ml) for 24 h. Secreted VEGF, IL-8 and
TNF in supernatants were measured with ELISA. As shown, IL-6 alone induced a
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significant increase in secretion of VEGF compared to untreated skin mast cells (Figure
6.6A). A similar increase in VEGF secretion was also observed from FcεRI-activated
mast cells pre-treated with IL-6 indicating an additive rather than potentiating effect. To
confirm that VEGF production was induced directly with IL-6, we treated non-sensitized
human skin mast cells with IL-6 (100 ng/ml), and measured changes in VEGF mRNA
expression at 1, 3, 6, 12, and 24 h by quantitative real-time PCR. As shown, VEGF
mRNA expression was increased >3-fold at 6 hours post IL-6, and remained elevated at
12 and 24 h compared to untreated mast cells (Figure 6.6B). We further demonstrate that
the IL-6-induced production of VEGF was inhibited with C188-9, the inhibitor of STAT3
phosphorylation at the activating tyrosine 705 (Figure 6.6C). Thus IL-6 alone can induce
VEGF production by a STAT3-dependent mechanism in human in situ-matured mast
cells. IL-6 alone did not induce IL-8 production, but significantly enhanced FcεRIinduced IL-8 secretion (Figure 6.6D). In contrast, IL-6 had no effect on production of
TNF (Figure 6.6E).
6.7 FCΕRI AND GP130 SIGNALS SYNERGIZE TO ENHANCE STAT3
PHOSPHORYLATION
STAT3 phosphorylation occurs at two main residues: tyrosine 705 and serine 727.
Initial phosphorylation at Y705 activates STAT3 (140, 141), whereas phosphorylation at
S727 is required for maximal transcriptional activity of STAT3 (142). To determine the
effect of FcεRI signaling on IL-6-induced STAT3 phosphorylation, human skin mast
cells were sensitized with anti-NP IgE, and treated with IL-6 (100 ng/ml), NP-BSA (100
ng/ml), or IL-6 + NP-BSA for 15 min. STAT3 phosphorylation at Y705 and S727 was
determined by Western blot analysis of whole cell lysates (Figure 6.7). As expected, IL6 alone strongly phosphorylated STAT3 at Y705, but, surprisingly, did not phosphorylate
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S727. Conversely, FcεRI signals alone did not phosphorylate STAT3 at Y705, but,
interestingly, did phosphorylate S727 albeit at low but detectable levels. Importantly,
phosphorylation of STAT3 at both Y705 and S727 was increased in human skin mast
cells treated with IL-6 + NP-BSA. Thus, signals from FcεRI and gp130 synergize to
enhance

STAT3

phosphorylation

at
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both

Y705

and

S727.

Figure 6.1: Human skin mast cells constitutively express membrane-bound IL-6Rα
and gp130. Human skin mast cells at rest were stained with PE-labeled anti-gp130 or
anti-IL-6Rα and analyzed by flow cytometry (A, C). Significance was determined by
analysis of Mean Fluorescence Intensity (MFI) (B, C). The effect of IL-10 on gp130
expression was determined by culturing human skin mast cells with IL-10 (10 ng/ml) for
24 h, and analyzing gp130 gene expression by quantitative real-time PCR (E) and surface
expression by flow cytometry (F). Bars represent mean ± S.E.M. of values from 3
separate experiments with mast cells from different donors. Significance was determined
with Student's t-test. *, p < 0.05 and **, p < 0.01.
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Figure 6.2: IL-6 induces STAT3 phosphorylation and SOCS3 expression via classical
signaling in human skin mast cells. To determine the functionality of membranebound gp130 and IL-6Rα, STAT3 phosphorylation and SOCS3 expression was analyzed
in IL-6-treated human skin mast cells. For comparison, parallel studies were performed
with IL-27, which also utilizes gp130. STAT3 phosphorylation was determined by SDSPAGE and Western blotting of whole cell lysates prepared from skin mast cells treated
with IL-6 or IL-27 at 1, 10, or 100 ng/ml for 15 min (A). STAT3 phosphorylation was
quantified with Western blot band intensities (B). SOCS3 expression was determined by
quantitative real-time PCR of total RNA from skin mast cells treated with IL-6
(100 ng/ml) (C) or IL-27 (D) for 1, 3, 6, 12, or 24 h. Fold change was calculated using the
2ΔΔCt method with B2M as the reference gene. >2-fold change was considered significant.
Bars represent mean ± S.E.M. of values from 3 separate experiments with mast cells from
different donors. Significance was determined with Student's t-test. **, p < 0.01 and
***, p < 0.001. Representative blot is shown.
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Figure 6.3: IL-6 does not induce or enhance FcεRI-induced degranulation of human
skin mast cells. Human skin mast cells were sensitized with anti-NP IgE, and challenged
with NP-BSA for 30 min. Degranulation was determined with β-hexosamindase release
assay. (A) Dose-dependent effect of IL-6 on FcεRI-induced degranulation induced with
NP-BSA (100 ng/ml). (B) Effect of IL-6 (100 ng/ml) on degranulation induced with NPBSA at 0.1, 1, 10, or 100 ng/ml. (C) Spontaneous release of IL-6. The amount of IL-6
and TNF in 7-day culture media of mast cells was quantified with ELISA. Each data
point represents mast cells from a single donor (n = 5). (D) Effect of endogenously
produced IL-6 on degranulation. Mast cells were cultured with neutralizing anti-IL6 mAb or isotype control (1 μg/ml) for 24, 48, or 72 h, and degranulation was determined.
Bars represent mean ± S.E.M. of values from at least 3 different experiments with mast
cells from different donors. Analysis was determined by Student's t-test.
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Figure 6.4: IL-6 potentiates FcεRI-induced PGD2 biosynthesis from human skin mast
cells. To determine the effect of IL-6 on PGD2 production, human skin mast cells were
sensitized with anti-NP IgE, pre-treated with IL-6 for 1 h, and then challenged with NPBSA for 30 min. IgE-sensitized human skin mast cells were pre-treated with IL-6 at 1, 10,
or 100 ng/ml, and then challenged with NP-BSA (A), or pre-treated with IL-6
(100 ng/ml) and challenged with NP-BSA at 1, 10, or 100 ng/ml (B). Secreted PGD2 in
cell-free supernatants was measured by enzyme immunoassay. Bars represent
mean ± S.E.M. of values from at least 3 separate experiments with mast cells from
different donors. Significance was determined with one-way ANOVA. *, p < 0.05;
**, p < 0.01.
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Figure 6.5: IL-6 enhances FcεRI-induced COX-2 expression and PGD2 biosynthesis by a
STAT3-dependent mechanism in human skin mast cells. IgE-sensitized mast cells were
pre-treated with IL-6 (100 ng/ml) for 1 h, and challenged with NP-BSA (100 ng/ml) for
1 h. The effect of IL-6 on FcεRI-induced expression of COX-2 (A, B) and COX-1 (C)
was determined by quantitative real-time PCR. (D) Western blotdemonstrating the
efficacy of C188-9 to inhibit IL-6-induced STAT3 phosphorylation. (E) Quantitative
real-time PCR analysis showing that C188-9 inhibits IL-6-enhanced COX-2 expression.
(F) Inhibition of IL-6-induced potentiation of FcεRI-induced PGD2biosynthesis with
C188-9 (25 μM). Graph bars represent mean ± S.E.M. of values from 3 separate
experiments with mast cells from different donors. Significance was determined with
one-way ANOVA. *, p < 0.05; **, p < 0.01; ***, p < 0.01; #, p < 0.001.
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Figure 6.6: IL-6 induces VEGF synthesis and enhances FcεRI-induced IL-8 production in
human skin mast cells. Human skin mast cells were sensitized with anti-NP IgE, pretreated with IL-6 at 1, 10, or 100 ng/ml for 1 h, and then challenged with NP-BSA
(100 ng/ml) for 24 h. Secreted VEGF (A, C), IL-8 (D) and TNF (E) in cell-free media
were measured with ELISA. (B) IL-6-induced VEGF mRNA expression was analyzed by
quantitative real-time PCR using total RNA isolated from mast cells treated with IL-6
(100 ng/ml) for 1, 3, 6, 12, and 24 h. >2-fold change was considered significant. (C)
C188-9 inhibits IL-6-induced VEGF production. Bars represent mean ± S.E.M. of values
from 3 separate experiments with mast cells from different donors. Significance was
determined by ANOVA. *, p < 0.05, **, p < 0.01, ***, p < 0.001, #, p < 0.0001.
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Figure 6.7: FcεRI and gp130 signals synergize to enhance STAT3 phosphorylation in
human skin mast cells. Western blot showing phosphorylation of STAT3 at tyrosine 705
and serine 727. Human skin mast cells were sensitized with anti-NP IgE, and then treated
with IL-6 (100 ng/ml), NP-BSA (100 ng/ml), or IL-6 + NP for 15 min. STAT3
phosphorylation was determined by SDS-PAGE and Western blot analysis of whole cell
lysates. Blot is representative of two separate experiments with mast cells from different
donors.
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CHAPTER 7
DISCUSSION- INTERLEUKIN-6 POTENTIATES FCΕRI-INDUCED
PGD2 BIOSYNTHESIS AND INDUCES VEGF FROM HUMAN IN-SITUMATURED SKIN MAST CELLS6
This study was designed to determine the ability of IL-6 to signal into in-situ
matured human skin mast cells, and characterize any functional effects of this signaling.
These experiments revealed the mechanism by which IL-6 exerts its effects on mast cells,
and how this signaling modifies mediator release.
Surface staining by flow cytometric analysis revealed that in-situ matured humans
skin mast cells constitutively express both components required for the functional IL-6
receptor; signal-transducing gp130 and ligand-binding IL-6Rα. This was not altogether
surprising, as it is believed that gp130 is ubiquitously expressed on most cell types while
expression of the alpha portion (IL-6Rα) is restricted to immune cells and hepatocytes
(54, 143). gp130 surface expression had been reported on BMMCs, but it was shown to
require administration of exogenous IL-10 (129). However, after examining the effects of
IL-10 on our human skin mast cells, it was revealed that while IL-10 does increase gp130
transcript, the surface expression remains unchanged. Interestingly, both IL-6Ra and
gp130 are found in the blood in soluble form (144). sIL-6Ra is produced upon proteolytic
cleavage by ADAM10/17, while sgp130 production is generally accomplished through
6

Parts of this chapter have been excerpted from the following research article:
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alternative splicing (145). Constitutive expression of the complete IL-6R on
huSMCs is consistent with the belief that most circulating sIL-6Ra originates from
myeloid cells, a lineage in which mast cells are included (143). In fact, most of the
harmful pathological effects of IL-6 are believed to be due to IL-6 trans-signaling rather
than classical signaling, which aligns with the expression patterns of membrane-bound
IL-6Ra and gp130. However, this does beg the question of how much, if any, sIL-6Ra
mast cells are capable of releasing into their environment. We do not address this topic
here, but it represents an interesting avenue to pursue in addition to exploring the
proteolytic activity of ADAM10/17 in huSMCs. However, it was shown recently that
human cord blood-derived mast cells (CBMC) spontaneously produce both sIL-6Rα and
sgp130 at similar levels. Notably, sIL-6Rα production was dose-dependently decreased
by IL-6 and showed significant reduction at 100 ng/ml. Inhibition of ADAMs 10 and 17
also resulted in a suppression of sIL-6Rα by LAD2 mast cells (73).
Upon discovering the constitutive expression of the complete IL-6 receptor, the
next step was to validate the ability of IL-6 to transmit a signal inside the cell. IL-6
signaling has been well-studied in other cell types, and at this point the pathway can be
considered canonical. Briefly, binding of IL-6 to IL-6Rα results in receptor dimerization
which activates both the JAK/STAT3 and SHP2/Gab/MAPK pathways. Here, we focus
solely on the characterization of the JAK/STAT3 pathway. The gp130-associated Janus
Kinases (Jaks). Activated Jaks then serve as docking sites for the SH2 domain-containing
Signal Transducer and Activator of Transcription 3 (STAT3), which are then
subsequently phosphorylated. Activated STAT3 then dimerizes and translocates to the
nucleus to exert its effects on gene expression. One of the genes upregulated by STAT3 is
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the Suppressor of Cytokine Signaling 3 (SOCS3), which acts as a negative regulator of
IL-6 signaling by inhibiting Jak. Since STAT3 phosphorylation is a hallmark of gp130
signaling, we used its activation status to assess the ability of IL-6R to signal into
huSMCs. For comparative analysis, we also assessed the ability of IL27, another gp130utilizing cytokine, to phosphorylate STAT3. Both IL-6 and IL-27 dose-dependently
increased the phosphorylation of STAT3 at Y705 after 15 minutes of activation.
Interestingly, when applied at the same concentrations, IL-6 induced STAT3
phosphorylation at twice the magnitude of IL-27. This is likely due to differences in
expression of the ligand-binding portion of each receptor. In data not shown here, the
expression of the ligand-binding portion of the IL-27 receptor, WSX-1, was undetectable
by flow cytometry surface staining (136). Assessment of SOCS3 mRNA induction by IL26 or IL-27 revealed similar results. IL-6 treatment caused a 362 ± 128-fold increase in
SOCS3 message while IL-27 treatment resulted in a 9 ± 0.3-fold increase. While both
cytokines increased SOCS3 expression, the level of upregulation corresponds to the
intensity of STAT3 phosphorylation. Together, this data shows that IL-6 initiates a much
stronger gp130 signal compared to other gp130-utilitzing cytokines. This is an interesting
phenomenon to consider since the purpose of SOCS3 is to attenuate JAK/STAT-utilizing
cytokine signaling. Thus, it appears that a strong gp130 signal induced by IL-6 requires
an equally strong response by SOCS3 to inhibit and regulate the inflammatory effects of
IL-6 signaling.
Knowing that the functional IL-6 receptor was constitutively expressed on the
surface of human skin mast cells, the next logical step was to address the effects of IL-6
on the release of inflammatory mediators. As outlined previously, mast cells generally
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release mediators in one of three ways: degranulation of pre-formed compounds, de-novo
synthesis of proteins, and biosynthesis of membrane-derived eicosanoids. These three
pathways generally occur temporally in that respective order. In contrast to a recent study
demonstrating that IL-6 could enhance degranulation of in-vitro-derived mast cells, we
show no evidence to support an enhancing effect in huSMCs (Desai/Metcalfe) We
arrived at this conclusion after testing the effect of IL-6 pre-treatment on huSMC
degranulation in two ways: (1) we pre-treated IgE-sensitized cells with IL-6 at 1, 10, or
100 ng/ml for 1 hr and then challenged them with NP-BSA (100 ng/ml) for 30 mins and
(2) we pre-treated IgE-sensitized cells with IL-6 (100 ng/ml) for 1 hr and then challenged
them with NP-BSA at 0.1, 1, 10, or 100 ng/ml for 30 mins. In both cases, cells showed no
significant changes in FcεRI-XL-dependent or independent degranulation as quantified
by beta-hexosaminidase assay. Of note, it was established by Oskeritzian et al. that mast
cells spontaneously produce and release IL-6 (71). Knowing this, we sought to determine
if endogenously-produced IL-6 was sensitizing the cells to the cytokine’s effects, perhaps
inhibiting exogenously added IL-6 from inducing degranulation. Cells were cultured for
24, 48, and 72 hours with media alone, isotype control, or IL-6 neutralizing antibody.
After challenge with NP-BSA and subsequent assay for degranulation, we determined
that endogenously produced IL-6 also did not affect huSMC degranulation. The lack of
an effect on degranulation is a surprising response, as STAT3 has been implicated in
mast cell degranulation by several studies (130–132). Specifically, it was reported that
STAT3 is critical for human mast cell degranulation while being disposable for murine
mast cell degranulation (132). Moreover, STAT3 itself has been closely linked to allergic
disease (131). This is unlikely, as STAT3 would be equally involved in mediating mast
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cell degranulation across species if it were indispensable. It is unclear why IL-6 has
inconsistent effects on degranulation in in-vitro-derived and in-situ matured human mast
cells, although several factors could contribute. Namely, the phenotype acquired by the
cells during maturation and development is certainly different between in-vivo and invitro grown mast cells. It is also possible that IL-6 has pleiotropic effects on mast cells of
different phenotypes or from different tissues, as it was shown to protect lung MCT cells
from apoptosis but had no effect on lung or skin MCTC mast cells (71). Additionally, IL-6
is typically added to CBMC cultures to induce in-vitro development which may prime the
mast cells to respond differently to exogenously administered IL-6 (146). In-situ-matured
human skin mast cells only required added SCF, not IL-6, when cultured in-vitro.
Together, the data generated here and that present in the current literature shows that
further experimentation is required to determine the role of IL-6 and STAT3 in mast cell
degranulation.
We next sought to determine the effect of IL-6 signaling on mast cell eicosanoid
production by specifically looking at biosynthesis of PGD2. PGD2 has been shown to be a
major contributor to the development of allergic asthma and is a known product of human
skin mast cell FcεRI crosslinking. In fact, robust quantities of PGD2 are produced in mere
minutes following FcεRI XL, where it is released into the environment to induce
bronchoconstriction and vasodilation. Pre-treatment with IL-6 at 1, 10, or 100 ng/ml and
subsequent FcεRI XL revealed the ability of IL-6 to dose-dependently potentiate the
production of PGD2 in human skin mast cells. Additionally, pre-treatment with IL-6 (100
ng/ml) and succeeding dose-dependent challenge with NP-BSA yielded similar results.
Notably, PGD2 production peaked when IL-6 pre-treated cells were challenged with NP-
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BSA at 10 ng/ml rather than the maximal 100 ng/ml. This suggests that maximal FcεRI
aggregation may actually be suboptimal for greatest PGD2 production. This is similar to
an effect seen in BMMCs in our own lab, where DNP-HSA challenge at maximal
amounts produces an inhibitory effect on degranulation.
As outlined previously, PGD2 is produced by the liberation of arachidonic acid
from the plasma membrane by cPLA2. Subsequently, it undergoes enzymatic
modification by cyclooxygenases into a common prostaglandin intermediate. Many
investigators have shown that COX-2 is the only inducible enzyme in this pathway, and it
is well-established that COX-1 is constitutively expressed regardless of cellular
stimulation (147). Knowing this, we hypothesized that IL-6 was causing this potentiating
effect on PGD2 production by modulating COX-2 expression. Indeed, after performing
RT-PCR on IL-6-treated cells, it was revealed that COX-2 was highest in those cells pretreated with IL-6 and then challenged with NP-BSA compared to IL-6 or NP-BSA alone.
The increase in transcript levels in IL-6 pre-treated cells compared with FcεRI XL alone
was significant, about two-fold. Concurrently, COX-1 message levels remained
consistent regardless of treatment as expected. Induction of COX-2 by IL-6 is consistent
with previous work done with macrophages, showing that IL-6 induced COX-2 and PGE
Synthase-1 (148). The ability of IL-6 to potentiate FcεRI-XL-dependent PGD2 production
is a novel finding and potentially represents a new mechanism in allergic disease. IL-6
levels are repeatedly correlated with severity of allergic disease, and mast cells and PGD 2
are known to contribute to asthma pathogenesis. Together, these findings suggest a
mechanism in which IL-6 contributes to asthma development and severity by increasing
PGD2 production in mast cells by classical signaling.
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The concurrent increases in COX-2 expression and PGD2 production by IL-6
suggest a STAT-3 dependent mechanism is responsible for these effects. However,
activation of the IL-6 receptor is known to cause signal transmission through other
pathways, including PI3K and MAPK (59). To determine if signaling through STAT3 is
solely responsible for increasing COX-2 and PGD2, we used an inhibitor of STAT Y705
phosphorylation, C188-9, to abolish IL-6 signaling. Pre-treatment of mast cells with
C188-9 and subsequent activation with IL-6 revealed C188-9’s ability to dosedependently inhibit gp130-induced STAT3 phosphorylation. Further experiments showed
that C188-9 abolished IL-6 induced COX-2 expression and PGD2 production (Fig. 4.5E
and F). The ability of C188-9 to selectively inhibit FcεRI-dependent IL-6-induced COX2 expression and PGD2 production proves this a STAT-3-dependent mechanism.
Chronologically, the final stage of FcεRI XL-dependent mediator release is the
production of de-novo cytokines, chemokines, and growth factors. Collectively, this
group of proteins is responsible for the late phase effects of allergic reactions like cellular
recruitment and subsequent infiltration. Literature on the IL-6 signaling pathway
provided clues to several proteins that may be IL-6-responsive. To isolate released
proteins, we pre-treated cells with IL-6 at varying concentrations and then activated them
with NP-BSA for 24 hrs. After activation, the cell-free supernatants were then subjected
to various ELISAs. Using this method, we identified the ability of IL-6 alone to increase
spontaneous production of VEGF and MCP-1, and to potentiate the FcεRI-XL-dependent
production of VEGF and IL-8. Of note, FcεRI XL appears to significantly decrease
production of MCP-1 in contrast to its effects on VEGF, IL-8, and TNFα (Fig. 4.6). The
differential response of de-novo produced proteins is very curious, and at this juncture we
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do not have a mechanistic explanation. However, the ability of IL-6 to induce the
production of some proteins and enhance the release of others most likely has to do with
the expression of response elements within the promoters of these genes. Additional
mechanistic studies are required to characterize this response. Another important
observation made during the course of this study was that human skin mast cells
spontaneously release significant amounts of VEGF, IL-8, and MCP-1. The spontaneous
release of VEGF in mast cells is not novel, but this is the first reported unstimulated
production of IL-8 and MCP-1 in human mast cells (149).
IL-6’s ability to potentiate spontaneous VEGF production independently of
FcεRI XL is a significant finding, as VEGF is one of the most potent pro-angiogenic
factors. In fact, when viewed separately VEGF, IL-8, and MCP-1 all have unique
physiological functions. But when viewed collectively, all three proteins play important
roles in angiogenesis. IL-8 is known to be associated with increased microvessel density
within tumors, while MCP-1 has been shown to promote angiogenesis in human
umbilical vein endothelial cells (HUVEC) by inducing MCP-1 inducible protein
(MCPIP) (150, 151). Additionally, mast cell-derived IL-8 has been shown to induce EMT
in thyroid cancer cells (152).
In summary, we show here that IL-6 potentiates FcεRI-dependent PGD2
production and induces VEGF and MCP-1 release. Additionally, IL-6 enhances FcεRIdependent VEGF and IL-8 production. Together, this data shows that IL-6 may
contribute to human allergic disease by increasing the production of inflammatory PGD2
released by pulmonary-resident mast cells, exacerbating asthmatic disease progression.
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Finally, the ability of IL-6 to increase angiogenesis-associated VEGF, IL-8, and MCP-1
release suggests a role for mast cells in developmental and pathological vessel growth.

70

CHAPTER 8
MATERIALS AND METHODS- HUMAN SKIN MAST CELLS
SPONTANEOUSLY SECERETE ANGIOGENESIS-ASSOCIATED
FACTORS7
Angiogenesis is defined as the formation of new vessels from pre-existing ones,
and serves vital physiological and pathological purposes. Vessel growth is required
during normal organism development, and is indispensable during tumor formation and
growth. Mast cells are known to be produces of VEGF, a potent stimulator of
angiogenesis. There is strong evidence that mast cells participate in pathological vessel
growth, and they have been shown to induce endothelial cell proliferation, migration, and
loop and tube formation. However, to better understand the role of mast cells in
angiogenesis, we sought to profile their secretion of angiogenesis-associated factors. The
methods used in this study were designed to identify spontaneous angiogenesisassociated protein production by human mast cells and investigate the effects of c-Kit and
FcεRI signaling on their release. All experiments were performed using in-situ-matured
human skin mast cells isolated in accordance with the University of South Carolina’s
Internal Review Board (IRB).
8.1 ISOLATION AND PURIFICATION OF HUMAN SKIN MAST CELLS
As described in Section 2.1.

7

Parts of this chapter have been excerpted from the following research article:
McHale, C., Mohammed, Z., Gomez, G. 2018. Human skin mast cells spontaneously secrete
angiogenesis-related factors. (In preparation).
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8.2 PROTEOME PROFILER
Mast cells (106 cells/ml) were sensitized or not with anti-NP IgE, pre-treated or
not with IL-6 (100 ng/ml) for one hour, and then activated or not with NP-BSA for 24 h
at 37oC in X-VIVO 15™ media containing SCF (100 ng/ml) and soybean trypsin
inhibitor (100 μg/ml) (SBTI; Sigma-Aldrich, St. Louis, MO). After the activation period,
mast cells and media were separated by centrifugation (2000 rpm x 5 min), and secreted
proteins in supernatant were measured by R&D Systems Angiogenesis Proteome Profiler.
First, the stamped identification number tab on each blot was removed to prevent
background fluorescence. After removing the protective sheets, membranes were blocked
in the provided wells with 2.0 mL of Array Buffer 7 for 1 hour on a rocking platform.
During blocking, sample is prepared by combining 0.75 mL of cell-free supernatant with
0.5 mL Array Buffer 4. Sample is then adjusted to a final volume of 1.5 mL with the
addition of 0.25 mL Array Buffer 5. Once each sample is prepared, 15 uL of Detection
Antibody Cocktail is added, mixed well, and incubated at RT for one hour. After
blocking is complete, Array Buffer 7 was aspirated from the wells and replaced with the
incubated sample/antibody mixture described above. The membrane is then incubated in
the sample/antibody mixture at 4 degrees C overnight on a rocking platform. After
overnight incubation, individual membranes were removed from the wells and placed in
separate plastic dishes with 20 mL of Wash Buffer each. The membranes were then
washed for 10 minutes on a rocking platform shaker. After aspirating off the Wash
Buffer, this was repeated two times with fresh buffer for a total of three washes. IRDye
800CW Streptavidin (LI-COR) was then diluted 1:2000 in Array Buffer 5, and 2 mL of
the diluted antibody was pipetted into each well to be used for staining. The membranes
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were then removed from the plastic dishes used for washing, and excess Wash Buffer
allowed to drain by blotting the lower edge onto absorbent paper. The membranes were
added to the wells containing antibody and stained in the dark for 30 minutes at room
temperature on a rocking platform. After secondary staining, the membranes were
washed as described above. The membranes were then removed from the wash container,
excess Wash Buffer was drained by blotting the lower edge on absorbent paper, and
imaging performed on an Odyssey Imager (LI-COR) at 84 μM Resolution, Medium
Quality, 0.0 mm Focus Offset, and 5 Intensity (adjusted as necessary). Image files were
then analyzed using Image Studio Version 3.1 (LI-COR) by comparing relative mean
fluorescence intensities from duplicate samples.
8.3 SECRETED PROTEIN ELISA
Mast cells (106 cells/ml) were sensitized with anti-NP IgE and activated or not
with NP-BSA for 24 h at 37 °C in X-VIVO 15™ media containing SCF (100 ng/ml) and
soybean trypsin inhibitor (100 μg/ml) (SBTI; Sigma-Aldrich, St. Louis, MO). After the
activation

period,

mast

cells

and

media

were

separated

by

centrifugation

(2000 rpm × 5 min), and the indicated proteins in supernatant were measured by using
commercial DuoSet enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems,
Minneapolis, MN) according to the manufacturer's protocol. Absorbance values at
450 nm were obtained with a BioTek Synergy HT microplate reader (BioTek, Winooski,
VT), and cytokine concentrations determined using Gen5 Data Analysis Software.
8.4 STATISTICAL ANALYSIS
As described in Section 2.8.
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CHAPTER 9
RESULTS- HUMAN SKIN MAST CELLS SPONTANEOUSLY
SECERETE ANGIOGENESIS-ASSOCIATED FACTORS8
Mast cells are known for their ability to produce and release a wide variety of
mediators into their environment. Stimulation by allergen, bacteria, and many other
compounds trigger this release in addition to the spontaneous release of select proteins.
This study was designed to identify and catalog the angiogenesis-related proteins
produced by human skin mast cells, based on their established spontaneous production of
VEGF, IL-8, and MCP-1 (153).
9.1 HUMAN SKIN MAST CELLS SPONTANEOUSLY SECRETE
ANGIOGENESIS-RELATED FACTORS
Human mast cells derived in culture from umbilical cord blood have been shown
to spontaneously secrete VEGF (149). In our studies, we also detect high levels of VEGF
from non-activated mast cells that were isolated and purified from human skin tissue
(153). To determine if other angiogenesis-related proteins were also secreted unprompted
from in situ-matured mast cells, human skin mast cells were washed and cultured in
serum-free medium containing only stem cell factor (SCF) and soybean trypsin inhibitor
(SBTI) to prevent proteolysis of secreted proteins (100). After a 24 h incubation period,
the cell-free medium was analyzed with the Human Angiogenesis Proteome Profiler™
Array (R&D Systems), which enabled us to detect the relative expression of 55 different
8

Parts of this chapter have been excerpted from the following research article:
McHale, C., Mohammed, Z., Gomez, G. 2018. Human skin mast cells spontaneously secrete
angiogenesis-related factors. (In preparation).
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angiogenesis-related proteins.

To our surprise, several proteins – CXCL16,

DPPIV, Endothelin-1, GM-CSF, IL-8, MCP-1, Pentraxin 3, Serpin E1, Serpin F1, TIMP1, Thrombospondin-1, uPA, and VEGF – were detected at relatively high levels (Figure
9.1).
To confirm the findings from the proteome array analysis and quantify the amount
of protein secreted, we cultured human skin mast cells in serum-free medium containing
SCF and SBTI for 24 h, and measured IL-8, VEGF, MCP-1, GM-CSF, TIMP-1, and
Serpin F1 with ELISA. As shown, all proteins analyzed were clearly detected (Figure
9.2). Noteworthy, TIMP-1 was produced at the highest quantities mirroring the signal
intensity of the proteome array, whereas VEGF was detected at the lowest level.
To determine if the spontaneously secreted proteins accumulate in the medium of
standard cultures to which SBTI is not normally added, we collected the medium from
established cultures of resting skin mast cells during regular weekly (every 7 days)
medium change and measured IL-8, VEGF, MCP-1, GM-CSF, TIMP-1, and Serpin F1
with ELISA. IL-6 and TNF were analyzed as positive and negative controls based on
previous studies (71, 153). As shown, all the proteins that were detected in the presence
of SBTI were also detected in the absence of proteolysis inhibitor (Figure 9.3). Some
variability was observed and some cultures appeared to produce very low to undetectable
amounts of a particular protein. This could be reflective of increased susceptibility to
proteolysis in the absence of SBTI and/or differences in cell density at the time the
medium was collected or age of the culture. Noteworthy, TIMP-1 and Serpin F1 were
detected at extremely high concentrations from all cultures tested. Thus, the secreted
proteins accumulate in cultures of human skin mast cells even in the absence of SBTI.
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Together these data demonstrate that several angiogenesis-related proteins in addition to
VEGF are spontaneously secreted from human in situ-matured skin mast cells.
9.2 DEPENDENCE ON STEM CELL FACTOR
Mast cell survival is dependent on Kit signals (10). To determine if the secretion
of the angiogenesis-related factors was due to stimulation of Kit receptor by exogenously
added SCF, we cultured human skin mast cells in medium containing SBTI without and
with SCF (100 ng/ml) for 24 h, and analyzed the cell-free medium by proteome array as
in Figure 9.1. As shown in Figure 9.4, secretion of CXCL16, DPPIV, and uPA was
similar in the presence or absence of SCF whereas secretion of endothelin-1, GM-CSF,
IL-8, MCP-1, and VEGF was almost completely abolished in the absence of SCF. In
addition, secretion of Pentraxin 3, Serpin E1, Serpin F1, TIMP-1, and Thrombospondin-1
was significantly reduced, but nevertheless produced at high levels in the absence of
SCF. These data demonstrate that the secretion of some proteins, but not others, could be
due to SCF stimulation of Kit receptor. However, because mast cells require SCF for
survival, the reduced production of these proteins could be reflective of diminished
cellular function overall in the absence of the SCF-induced survival signal.
9.3 EFFECT OF FCΕRI CROSSLINKING ON SECRETION OF
ANGIOGENESIS-RELATED PROTEINS
Mast cell activation is generally associated with FcεRI crosslinking.

To

determine the effect of FcεRI crosslinking on secretion of angiogenesis-related proteins
particularly those found to be spontaneously secreted, we performed a proteome array
analysis on medium collected from anti-DNP IgE-sensitized human skin mast cells that
were challenged with DNP-HSA (100 ng/ml) for 24 h. As expected, FcεRI crosslinking
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further increased the production of GM-CSF, IL-8, Serpin E1, and VEGF, and induced
the production of others like Amphiregulin and MMP-8 (Figure 9.5A). Surprisingly,
CXCL16, Endothelin-1, Serpin F1, Thrombospondin-1, MCP-1, and Pentraxin-3 were
significantly inhibited by FcεRI crosslinking (Figure 9.5B). To confirm the array data,
we repeated the experiment and measured IL-8, VEGF, TIMP-1, GM-CSF, Serpin F1,
and MCP-1 with ELISA. As shown, IL-8, VEGF, TIMP-1, and GM-CSF were increased
following FcεRI crosslinking, whereas Serpin F1 and MCP-1 production was inhibited
(Figure 9.6). Thus, FcεRI crosslinking has positive and negative effects on production of
angiogenesis-related factors from mast cells.
9.4 EFFECT OF GP130 SIGNALING ON SECRETION OF ANGIOGENESISRELATED PROTEINS
We have previously shown that human skin mast cells spontaneously secrete
measureable quantities of VEGF and IL-8 (153) in addition to MCP-1 (not shown).
Moreover, IL-6 signaling through gp130 increases the spontaneous production of VEGF
and MCP-1 while potentiating the FcεRI-dependent release of IL-8. To determine the
effect of IL-6 on the secretion of other angiogenesis-related proteins, we performed a
proteome array analysis on medium collected from human skin mast cells that were
cultured with exogenous IL-6 (100 ng/ml) for 24 h. As expected, gp130 signaling
increased the spontaneous production of VEGF (Figure 9.7A) and MCP-1 (Figure 9.7B)
without affecting IL-8 secretion (not shown). Surprisingly, IL-6 did not significantly
affect secretion of any other proteins detected. Thereby, exogenous IL-6 increases
spontaneous

VEGF

and

MCP-1

secretion
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Figure 9.1: Human skin mast cells spontaneously secrete angiogenesis-related factors.
Skin mast cells were cultured at 106/ml for 24 h with SCF (100 ng/ml) and SBTI (100
μg/ml). Supernatant was then subjected to the Human Angiogenesis Proteome Profiler
Array (R&D Systems) to allow for the detection of up to 55 different angiogenesisrelated proteins. Bars represent mean ± SEM of two experiments using cells from
cultures obtained from individual donors.
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Figure 9.2: Human skin mast cells spontaneously secrete IL-8, VEGF, MCP-1, TIMP-1,
GM-CSF, and Serpin F1. Human skin mast cells were cultured in serum-free medium
containing SCF and SBTI for 24 h, and the indicated proteins were measured by ELISA.
Data points represent protein concentrations from cultures obtained from three individual
donors while horizontal bars indicate mean.
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Figure 9.3: Angiogenesis-related factors accumulate in medium of standard cultures
without SBTI. Medium from established cultures of resting human skin mast cells with
added SCF (100 ng/ml) only was collected during regularly weekly (every 7 days)
feeding. The resulting supernatants were subjected to ELISA for the measurement of the
indicated secreted proteins. Data points represent protein concentrations from cultures
obtained from individual donors as available.
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Figure 9.4: c-Kit signaling differentially regulates angiogenesis-related protein
production from human skin mast cells. To determine the effect of SCF on protein
production, skin mast cells were cultured for 24 hr at 106/ ml plus SBTI (100 μg/ml) with
or without SCF (100 ng/ml). Supernatant was then subjected to the Human Angiogenesis
Proteome Profiler Array (R&D Systems) to allow for the detection of 55 different
angiogenesis-related proteins. Bars represent mean ± S.E.M. of values from 2 separate
experiments with mast cells obtained from i donors. Significance was determined by
Student's t-test. *p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.0001.
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Figure 9.5: FcεRI signaling differentially regulates angiogenesis-related protein
production from human skin mast cells. To determine the effect of IgE receptor
crosslinking on protein production, skin mast cells were cultured for 24 hr at 106/ ml plus
SCF (100 ng/ml) and SBTI (100 μg/ml) with or without antigen challenge (NP-BSA 100
ng/ml). Supernatant was then subjected to the Human Angiogenesis Proteome Profiler
Array (R&D Systems) to allow for the detection of secreted protein. Bars represent
mean ± S.E.M. of values from 2 separate experiments with mast cells obtained from
individual donors. Significance was determined by Student's t-test. *p < 0.05, **p < 0.01,
***p < 0.001, #p < 0.0001.
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Figure 9.6: FcεRI crosslinking has opposing effects on spontaneous angiogenesis-related
protein production from human skin mast cells. To verify the results seen in the Proteome
Profiler, cells were cultured for 24 hr at 106/ ml plus SCF (100 ng/ml) and SBTI (100
μg/ml) with or without antigen challenge (NP-BSA 100 ng/ml). Supernatant was then
subjected to the indicated ELISAs to quantify the previously observed effects. Linked
data points represent protein concentrations from cultures obtained from individual
donors (n = 3).
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Figure 9.7: IL-6 signaling increases spontaneous VEGF and MCP-1 production from
human skin mast cells. To determine the effect of IL-6 on protein production, skin mast
cells were cultured for 24 hr at 106/ ml plus SCF (100 ng/ml) and SBTI (100 μg/ml) with
or without IL-6 (100 ng/ml). Supernatant was then subjected to the Human Angiogenesis
Proteome Profiler Array (R&D Systems) for protein detection. Bars represent
mean ± S.E.M. of values from 2 separate experiments with mast cells obtained from
individual donors. Significance was determined by Student's t-test. **p < 0.01.
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CHAPTER 10
DISCUSSION- HUMAN SKIN MAST CELLS SPONTANEOUSLY
SECRETE ANGIOGENESIS-ASSOCIATED FACTORS9
Mast cells are believed to play a key role in angiogenesis. Current knowledge
suggests that mast cells contribute to vessel growth by producing and releasing several
angiogenesis-related proteins including VEGF, FGF, IL-8, TIMPs, and basementmembrane degrading enzymes (96). Both VEGF and FGF are particularly potent inducers
of angiogenesis, enacting their effects even at low levels (154). At present, researchers
have identified dozens of proteins outside of those mentioned that are involved in the
regulation of angiogenesis. However, data on the full range of angiogenesis-related
proteins produced by mature human mast cells is deficient. We previously showed that
human skin mast cells spontaneously produce VEGF, IL-8, and MCP-1, suggesting an
unexplored role for mast cells in vessel growth (153). Thus, the goal of the present study
was to identify and catalog the production of angiogenesis-related proteins by in-situmatured human skin mast cells.
Our lab’s unique ability to isolate and culture in-situ matured human mast cells
again afforded us the opportunity to study cells that were differentiated and matured in
physiological conditions. For this reason, we can confidently draw parallels between how
our human skin mast cells function in-vitro and how they may function in-vivo. This is in
9

Parts of this chapter have been excerpted from the following research article:
McHale, C., Mohammed, Z., Gomez, G. 2018. Human skin mast cells spontaneously secrete
angiogenesis-related factors. (In preparation).
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stark contrast to using a mouse bone marrow-derived mast cell, mast cell line
(HMC-1, LAD2) or even a human CD34+ cord blood-derived mast cell (CBMC), which
are artificially differentiated. These in-vitro-matured MCs can have marked differences
from in-situ-matured cells, ranging from disparities in relative mediator production to
lacking surface expression of the cell type-defining IgE receptor FcεRI (112). Using this
model, we demonstrate that resting in-situ-matured human skin mast cells spontaneously
secrete CXCL16, DPPIV, Endothelin-1, GM-CSF, IL-8, MCP-1, Pentraxin 3, Serpin E1,
Serpin F1, TIMP-1, Thrombospondin-1, uPA, and VEGF (Table 10.1). Furthermore,
production of these factors is differentially regulated by both c-Kit and FcεRI signaling.

Table 10.1: Spontaneously produced angiogenesis-associated proteins from huSMCs.
Protein
CXCL16
DPPIV
Endothelin-1
GM-CSF
IL-8
MCP-1
Pentraxin 3 (PTX3)
Serpin E1
Serpin F1
TIMP-1
Thrombospondin-1
uPA
VEGF

Gene ID
58191
1803
1906
1437
3576
6347
5806
5054
5176
7076
7057
5328
7422

Alternate Nomenclature
CD26
ET-1
CXCL8
CCL2
TSG-14
PAI-1
PEDF
TSP-1

To create this profile of angiogenesis-related proteins produce by mature human mast
cells, we approached this study with an inverted pyramid strategy; beginning by testing
for a wide variety of mediators and then using this profile to narrow down specific
protein targets. To do this, we employed the use Human Angiogenesis Proteome
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Profiler™ (R&D Systems). Allowing for the identification of up to 55 proteins at a time,
these assays utilize a membrane coated with sets of specific capture antibodies to identify
multiple proteins of interest in a western blot-like manner. The resulting output is
twofold: (1) whether or not the cell type is producing each protein, and (2) the relative
amount of secreted protein. Since this assay does not quantify the concentration of each
factor, the Proteome Profiler data is best interpreted when confirmed by quantifiable
methods such as ELISA.
As aforementioned, our initial goal was to identify spontaneous release of
angiogenic proteins by resting human skin mast cells. After culturing cells from multiple
donors in serum-free media with only added SCF (100 ng/ml) and SBTI (100 μg/ml) for
24 hours, the resulting supernatant was subjected to the Proteome Profiler. The Profiler
determined spontaneous secretion of CXCL16, DPPIV, Endothelin-1, GM-CSF, IL-8,
MCP-1, Pentraxin 3, Serpin E1, Serpin F1, TIMP-1, Thrombospondin-1, uPA, and
VEGF. Notably, the relative levels of expression appeared to be highly variable from
protein to protein. Some factors, such as TIMP-1, were present in robust amounts,
whereas other factors like VEGF and uPA appeared at fractional levels of TIMP-1. Also
of note is that these proteins are a mix of pro- and anti-angiogenic factors, suggesting a
role for mast cells in the regulation of angiogenesis rather than just its initiation and
perpetuation. We confirmed the findings from the profiler array by performing ELISAs
on cell-free supernatants from human skin mast cells cultured for 24 h in serum-free
media with SCF (100 ng/ml) and SBTI (100 μg/ml). As shown in Figure 7.2, IL-8,
VEGF, MCP-1, GM-CSF, TIMP-1, and Serpin F1 were all detectable by ELISA. As in
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the profiler, TIMP-1 was produced at the highest concentrations compared to the other
proteins.
In addition to the secretion of de-novo produced proteins and biosynthesized
eicosanoids, mast cells also release the contents of their cytoplasmic granules upon FcεRI
XL activation. It was shown that mast cells sometimes spontaneously release these
granules and the compounds contained within them, including proteases (155).
Importantly, these endogenous proteases have been proven to be responsible for the
degradation of mast cell-produced cytokines (100). To determine if the spontaneously
secreted proteins accumulate in the media of human skin mast cells without added SBTI,
we collected the media from established cultures during weekly feedings (occurs every 7
days). ELISA revealed that all proteins detected in the presence of SBTI- IL-8, VEGF,
MCP-1, GM-CSF, TIMP-1, and Serpin F1, were detectable in the absence of the
proteolytic inhibitor SBTI. This shows that these proteins are not subject to degradation
by endogenous mast cell proteases, or are only slightly susceptible to digestion. While
there were significant differences in the concentrations of proteins from culture to
culture, this can be attributed to disparity in cell concentration, culture age, and
susceptibility to proteolysis.
The presence of so many spontaneously produced proteins in the supernatant of
resting mast cells was a surprising discovery that merited further investigation. Since the
media used contains no serum or growth factors outside of the required SCF, we sought
to determine the involvement of c-Kit (SCFR) signaling in angiogenesis-related protein
production. It is known that SCF plays an important role in mast cell activation and proinflammatory mediator release, so it possible that c-Kit signaling contributes to
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angiogenesis-related protein secretion (15). Cells were incubated for 24 in serum-free
media plus SBTI (100 μg/ml) with or without SCF (100 ng/ml). After incubation, the
cell-free supernatants were subjected to the Proteome Profiler. Comparison of protein
secretion in SCF compared to media only samples revealed an interesting effect; c-Kit
signaling differentially regulates the production of each protein. CXCL16, DPPIV, and
uPA production is SCF-independent, Pentraxin 3, Serpin E1, Serpin F1, TIMP-1, and
Thombospondin-1 production is partially SCF-dependent, and GM-CSF, IL-8, MCP-1,
and VEGF production is SCF-dependent. This discovery further emphasizes the
importance of SCF in mast cell function, and reinforces the idea that it is a critical
molecule for mediator production (15). While this is an interesting mechanism to
consider, ultimately the point is moot because SCF is required for mast cell expansion,
differentiation, and survival (7). Without added SCF in vitro, both human and murine
mast cells will lose function, viability, and ultimately perish (10). Thus, the effects of cKit signaling on protein production in the absence of SCF are irrelevant.
Knowing that human skin mast cells spontaneously produce measurable quantities
of angiogenesis-related proteins, the logical next step was to investigate how allergic
activation modulates this function. To achieve this, we challenged IgE-sensitized human
skin mast cells with NP-BSA or media control and cultured them for 24 h in serum-free
media plus SCF (100 ng/ml) and SBTI (100 μg/ml). The cell-free supernatants were
again subjected to the Proteome Profiler and the FcεRI XL samples were compared to
spontaneous controls. Analysis revealed that FcεRI XL differentially regulated
angiogenesis-related protein production. Protein secretion was increased, decreased, or
remained

unaffected.

Those

increased

by
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Amphiregulin, GM-CSF, IL-8, TIMP-1, and Serpin E1, while CXCL16, Endothelin-1,
Serpin F1, Thrombospondin-1, MCP-1, and Pentraxin 3 were decreased. The increases in
the production of the aforementioned factors were not surprising, as it is welldocumented that FcεRI XL induces the release of many de-novo synthesized proteins
(28). However, the reduction in MCP-1 and Serpin F1 levels upon allergic activation is a
novel observation since there is currently no evidence for IgE receptor crosslinking
decreasing mediator production. To confirm the results of the Proteome Profiler, we
repeated the experiment and assayed the cell-free supernatants for the indicated proteins
by ELISA. We validated the increases in seen in IL-8, VEGF, TIMP-1, and GM-CSF
upon FcεRI XL, and the decreases seen in Serpin F1 and MCP-1. The consequences of
FcεRI XL on angiogenic mediator production are interesting to consider, especially due
to the wide range of functions performed by the affected proteins. For example, FcεRI
XL increases VEGF, which induces potent endothelial proliferation and promotes
angiogenesis (156). Conversely, TIMP-1 production is also increased by FCεRI XL, yet
TIMP-1 functions to hamper angiogenesis by inhibiting the proteases responsible for
degrading the basement membrane (157). Even the decrease in MCP-1 and Serpin F1
upon FcεRI tell a dichotomous story, as MCP-1 is strongly angiogenic due to its
induction of the transcription factor MCP-1 induced protein (MCPIP) (151), while Serpin
F1 inhibits vessel growth by decreasing VEGFR expression (158). These seemingly
opposing effects again suggest that mast cells may play a regulatory role in vessel
growth, perhaps serving to both initiate and attenuate angiogenesis. This contrasts with
the general current view that mast cells serve a primarily pro-angiogenic purpose in-vivo
(96). A more nuanced role for mast cells in angiogenesis would not be surprising since
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vessel growth is ubiquitously associated with several diseases in which mast cells have
been implicated (3, 80, 159). Specifically, angiogenesis is a hallmark of pathology in
asthma where vessel growth occurs during airway remodeling (160). During asthmatic
airway remodeling, the local balance of pro- and anti-angiogenic factor expression shifts
heavily towards pro-, including increased local VEGF expression and concentration (161,
162). Similarly, increased levels of VEGF and Serpin F1 are present in children who
suffer from chronic food allergy compared to non-allergic individuals (163). While mast
cells have been inculpated as a source of this increased VEGF, our results suggest they
contribute much more to the local tissue (153).
Our final goal was to examine the effect of gp130 signaling, specifically via IL-6,
on angiogenesis-related protein production. Increased IL-6 levels are associated with
many inflammatory conditions including allergic disease and cancer, where angiogenesis
is key to tumor growth(54). We had previously shown that IL-6 signaling alone increased
human skin mast cell spontaneous production of VEGF and MCP-1, and potentiated
FcεRI-XL-dependent IL-8 release. Supporting this notion, IL-6 has been shown to
increase VEGF production in many studies, particularly those involving cancerous cells
or tumors (164–166). To investigate how IL-6 modulates angiogenic protein release in
human skin mast cells, we cultured cells for 24 h in media with or without IL-6 (100
ng/ml) plus SCF (100 ng/ml) and SBTI (100 μg/ml). The resulting cell-free supernatant
was subjected to the Proteome Profiler, and relative protein levels were compared
between IL-6-treated and control samples. Surprisingly, activation by IL-6 only revealed
increases in the production of VEGF and MCP-1, corroborating our previous
observations (153). While this data reaffirms the effects of IL-6 signaling on human skin
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mast cell VEGF and MCP-1 production, we failed to identify any new angiogenesisassociated targets of gp130 signaling. MCP-1 induced protein (MCPIP) appears to be
directly linked to VEGF production as knocking it down results in decreased VEGF and
HIF-1 expression (151). Additionally, MCP-1 was shown to promote tumor metastasis in
murine breast cancer cells (167). This suggests the possibility of a novel mechanism of
IL-6-mast cell-MCP-1-induced angiogenesis.
Collectively, this study proves that in-situ matured human skin mast cells: (1)
spontaneously produce significant amounts of angiogenesis-related proteins, (2) FcεRI
XL differentially regulates this spontaneous production, and (3) IL-6 signaling
significantly enhances the spontaneous production of VEGF and MCP-1. These data
taken together strongly suggest a major regulatory role for mast cells in angiogenesis, and
further expand the known repertoire of human mast cell mediators. The wide range of
angiogenesis-associated proteins produced shows that we must now consider mast cells
as contributing to both the initiation and attenuation of vessel growth. Finally, due to
increased mast cell numbers in the tumor microenvironment and the importance of vessel
growth during tumor progression and metastasis, this data advocates a renewed
importance

for

mast

cells

in

tumor
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CHAPTER 11
CONCLUSIONS
The data discussed here represents a new understanding of mast cell function in
both allergic and non-allergic disease. Most significantly, we have characterized a novel
IL-6 signaling pathway in in-situ matured human skin mast cells and reported its effects
on mediator production. In a STAT-3-dependent manner, IL-6 potentiates PGD2
biosynthesis by upregulating COX-2 expression. While IL-6 has no effect on
degranulation, it does increase production of spontaneous VEGF and MCP-1 while
potentiating FcεRI-XL-dependent IL-8 production. Mechanistically, we have shown that
simultaneous antigen challenge and administration of IL-6 phosphorylates both the Y705
and S727 residues on STAT-3, required for its maximal transcriptional activity. The
ubiquity of IL-6’s presence during inflammatory conditions such as allergic disease,
rheumatoid arthritis, and obesity represents a new link to how mast cells may contribute
to these diseases. Importantly, this study also provided us with the knowledge that human
skin mast cells spontaneously produce significant amounts of VEGF, MCP-1, and IL-8all angiogenesis-associated factors.
We next demonstrated that mast cells, in addition to VEGF, MCP-1, and IL-8,
spontaneously produce substantial amounts of several angiogenesis-related proteins. This
finding, in addition to the well-known fact that mast cells are found proximally to blood
vessels, suggests a role for mast cells in both developmental and pathogenic
angiogenesis. Moreover, we showed that the production of these angiogenesis-related
93

proteins can be differentially by FcεRI XL. FcεRI increased the release of
Amphiregulin, GM-CSF, IL-8, and Serpin E1, but decreased production of CXCL16,
Endothelin-1, Serpin F1, Thrombospondin-1, MCP-1, and Pentraxin 3. These effects of
allergic activation further enforce a potential role for mast cells in vessel growth.
Finally, we show opposing effects of the polyphenol Resveratrol on proinflammatory mediator production in human skin mast cells. At low concentration,
Resveratrol inhibited PGD2 biosynthesis but significantly enhanced TNFα production.
These antagonistic effects emphasize the importance of understanding the full spectrum
of consequences that Resveratrol could have on inflammation. While it may be effective
in dampening inflammation of one etiology, it may be ineffective or even aggravating to
another.
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CHAPTER 12
FUTURE STUDIES
Our current model of isolating and culturing in-situ-matured human skin mast
cells to purity is the most accurate in-vitro representation of this cell type’s behavior in
the human body. However, this still means that the findings detailed in this Dissertation
exclusively address the in-vitro behavior of mature human mast cells. The logical next
step is to adapt these findings to in-vivo mouse models.
We have shown that both IL-6 and Resveratrol affect PGD2 production, which has
been chiefly implicated in the pathogenesis of asthma. It follows that examining the
effects of IL-6 and Resveratrol in a mouse model of asthma, such as in the ovalbumininduced model, would be appropriate. Conversely, one could take many different
approaches to investigating the effects of mast cells on angiogenesis in-vivo. In
particular, the use of a mouse model of cancer (of which there are many) to study
pathological angiogenesis could prove exceptionally fruitful.
The IL-6 signaling pathway in human skin mast cells still requires further
elucidation in which our in-vitro model will be useful. There are undoubtedly many more
targets of IL-6 signaling, and a microarray or BioPlex would be an efficient way to
determine additional IL-6-responsive genes. We would also like to investigate the ability
of human skin mast cells to produce soluble IL-6Rα and gp130, which can be
accomplished by ELISA. Understanding the contributing of mast cells to local and
systemic IL-6 signaling could prove vital in targeting this pathway during clinical anti95

inflammatory intervention. Finally, since recent emphasis has been put on understanding
cellular metabolism, we would like to study how IL-6 affects mast cell mitochondrial
function and glycolysis. With this data, we believe we could produce a specific snapshot
of the mechanism and outcome of IL-6 signaling in human skin mast cells.

96

REFERENCES
1. Maciel, T. T., I. C. Moura, and O. Hermine. 2015. The role of mast cells in cancers.
F1000Prime Rep. 7: 9.
2. Shi, M. a., and G.-P. Shi. 2012. Different Roles of Mast Cells in Obesity and Diabetes:
Lessons from Experimental Animals and Humans. Front. Immunol. 3: 1–12.
3. Liu, J., A. Divoux, J. Sun, J. Zhang, K. Clément, J. N. Glickman, G. K. Sukhova, P. J.
Wolters, J. Du, C. Z. Gorgun, A. Doria, P. Libby, R. S. Blumberg, B. B. Kahn, G. S.
Hotamisligil, and G.-P. Shi. 2009. Genetic deficiency and pharmacological stabilization
of mast cells reduce diet-induced obesity and diabetes in mice. Nat. Med. 15: 940–5.
4. Krystel-Whittemore, M., K. N. Dileepan, and J. G. Wood. 2016. Mast cell: A multifunctional master cell. Front. Immunol. 6.
5. Galli, S. J., and M. Tsai. 2010. Mast cells in allergy and infection: Versatile effector
and regulatory cells in innate and adaptive immunity. Eur. J. Immunol. 40: 1843–1851.
6. Amin, K. 2012. The role of mast cells in allergic inflammation. Respir. Med. 106: 9–
14.
7. da Silva, E. Z. M., M. C. Jamur, and C. Oliver. 2014. Mast Cell Function: A New
Vision of an Old Cell,.
8. Dahlin, J. S., and J. Hallgren. 2015. Mast cell progenitors: Origin, development and
migration to tissues. Mol. Immunol. 63: 9–17.
9. Hallgren, J., and M. F. Gurish. 2011. Mast cell progenitor trafficking and maturation.
Adv. Exp. Med. Biol. 716: 14–28.
10. Galli, S. J., M. Tsai, B. K. Wershil, S. Y. Tam, and J. J. Costa. 1995. Regulation of
mouse and human mast cell development, survival and function by stem cell factor, the
ligand for the c-kit receptor. Int Arch Allergy Immunol 107: 51–53.
11. Liang, J., Y. L. Wu, B. J. Chen, W. Zhang, Y. Tanaka, and H. Sugiyama. 2013. The
C-Kit receptor-mediated signal transduction and tumor-related diseases. Int. J. Biol. Sci.
9: 435–443.
12. Cardoso, H. J., M. I. Figueira, S. Correia, C. V. Vaz, and S. Socorro. 2014. The
SCF/c-KIT system in the male: Survival strategies in fertility and cancer. Mol. Reprod.
Dev. 81: 1064–1079.
13. Okayama, Y., and T. Kawakami. 2006. Development, migration, and survival of mast
cells. Immunol. Res. 34: 97–115.
14. Dahlin, J. S., M. Ekoff, J. Grootens, L. Löf, R. M. Amini, H. Hagberg, J. S.
Ungerstedt, U. Olsson-Strömberg, and G. Nilsson. 2017. KIT signaling is dispensable for
human mast cell progenitor development. Blood 130: 1785–1794.
15. Ito, T., D. Smrž, M.-Y. Jung, G. Bandara, A. Desai, Š. Smržová, H. S. Kuehn, M. a
Beaven, D. D. Metcalfe, and A. M. Gilfillan. 2012. Stem cell factor programs the mast
cell activation phenotype. J. Immunol. 188: 5428–37.
16. Moon, T. C., C. D. St Laurent, K. E. Morris, C. Marcet, T. Yoshimura, Y. Sekar, and
A. D. Befus. 2010. Advances in mast cell biology: New understanding of heterogeneity

97

and function. Mucosal Immunol. 3: 111–128.
17. Kambe, N., H. Hiramatsu, M. Shimonaka, H. Fujino, R. Nishikomori, T. Heike, M.
Ito, K. Kobayashi, Y. Ueyama, N. Matsuyoshi, Y. Miyachi, and T. Nakahata. 2004.
Development of both human connective tissue-type and mucosal-type mast cells in mice
from hematopoietic stem cells with identical distribution pattern to human body. Blood
103: 860–867.
18. Irani, A. M., and L. B. Schwartz. 1994. Human mast cell heterogeneity. Allergy Proc.
Off. J. Reg. State Allergy Soc. 15: 303–308.
19. Theoharides, T. C., K. D. Alysandratos, A. Angelidou, D. A. Delivanis, N.
Sismanopoulos, B. Zhang, S. Asadi, M. Vasiadi, Z. Weng, A. Miniati, and D.
Kalogeromitros. 2012. Mast cells and inflammation. Biochim. Biophys. Acta - Mol. Basis
Dis. 1822: 21–33.
20. Siraganian, R. P., R. O. de Castro, E. A. Barbu, and J. Zhang. 2010. Mast cell
signaling: The role of protein tyrosine kinase Syk, its activation and screening methods
for new pathway participants. FEBS Lett. 584: 4933–4940.
21. Wernersson, S., and G. Pejler. 2014. Mast cell secretory granules: Armed for battle.
Nat. Rev. Immunol. 14: 478–494.
22. Benyon, R. C., C. Robinson, and M. K. Church. 1989. Differential release of
histamine and eicosanoids from human skin mast cells activated by IgE-dependent and
non-immunological stimuli. Br. J. Pharmacol. 97: 898–904.
23. Sayama, K., M. Diehn, K. Matsuda, C. Lunderius, M. Tsai, S. Y. Tam, D. Botstein, P.
O. Brown, and S. J. Galli. 2002. Transcriptional response of human mast cells stimulated
via the Fc(epsilon)RI and identification of mast cells as a source of IL-11. BMC.Immunol.
3: 5.
24. Galli, S. J., P. Starkl, T. Marichal, and M. Tsai. 2016. Mast cells and IgE in defense
against venoms: Possible “good side” of allergy? Allergol. Int. 65: 3–15.
25. Schick, B., and K. F. Austen. 1985. Pharmacological modulation of activationsecretion of rat serosal mast cells by chymase, an endogenous secretory granule protease.
Immunology 56: 513–22.
26. Ali, H. 2010. Regulation of human mast cell and basophil function by anaphylatoxins
C3a and C5a. Immunol. Lett. 128: 36–45.
27. Moon, T. C., A. Dean Befus, and M. Kulka. 2014. Mast cell mediators: Their
differential release and the secretory pathways involved. Front. Immunol. 5.
28. Moon, T. C., a D. Befus, and M. Kulka. 2014. Mast cell mediators: their differential
release and the secretory pathways involved. Front. Immunol. 5: 569.
29. Borish, L., and B. Z. Joseph. 1992. Inflammation and the allergic response. Med.
Clin. North Am. 76: 765–787.
30. Carroll, N. G., S. Mutavdzic, and A. L. James. 2002. Increased mast cells and
neutrophils in submucosal mucous glands and mucus plugging in patients with asthma.
Thorax 57: 677–682.
31. Castells, M. 2006. Mast Cell Mediators in Allergic Inflammation and Mastocytosis.
Immunol. Allergy Clin. North Am. 26: 465–485.
32. Fukami, H., H. Okunishi, and M. Miyazaki. 1998. Chymase: Its pathophysiological
roles and inhibitors. Curr. Pharm. Des. 4: 439–453.
33. Boyce, J. A. 2005. Eicosanoid mediators of mast cells: Receptors, regulation of
synthesis, and pathobiologic implications. Chem. Immunol. Allergy 87: 59–79.

98

34. Dichlberger, A., S. Schlager, K. Maaninka, W. J. Schneider, and P. T. Kovanen.
2014. Adipose triglyceride lipase regulates eicosanoid production in activated human
mast cells. J. Lipid Res. 55: 2471–2478.
35. Fonteh, A. N., J. M. Samet, and F. H. Chilton. 1995. Regulation of arachidonic acid,
eicosanoid, and phospholipase A2 levels in murine mast cells by recombinant stem cell
factor. J Clin.Invest 96: 1432–1439.
36. Schuligoi, R., R. Schmidt, G. Geisslinger, M. Kollroser, B. A. Peskar, and A.
Heinemann. 2007. PGD2metabolism in plasma: Kinetics and relationship with bioactivity
on DP1 and CRTH2 receptors. Biochem. Pharmacol. 74: 107–117.
37. Oguma, T., K. Asano, and A. Ishizaka. 2008. Role of Prostaglandin D2 and Its
Receptors in the Pathophysiology of Asthma. Allergol. Int. 57: 307–312.
38. Arima, M., and T. Fukuda. 2011. Prostaglandin D2 and TH2 Inflammation in the
Pathogenesis of Bronchial Asthma. Korean J. Intern. Med. 26: 8–18.
39. Matsuoka, T. 2000. Prostaglandin D2 as a Mediator of Allergic Asthma. Science (80-.
). 287: 2013–2017.
40. Fajt, M. L., S. L. Gelhaus, B. Freeman, C. E. Uvalle, J. B. Trudeau, F. Holguin, and
S. E. Wenzel. 2013. Prostaglandin D2pathway upregulation: Relation to asthma severity,
control, and TH2 inflammation. J. Allergy Clin. Immunol. 131.
41. Langcake, P., and R. J. Pryce. 1977. The production of resveratrol and the viniferins
by grapevines in response to ultraviolet irradiation. Phytochemistry 16: 1193–1196.
42. Bonnefont-Rousselot, D. 2016. Resveratrol and cardiovascular diseases. Nutrients 8.
43. Das, S., and D. K. Das. 2007. Anti-inflammatory responses of resveratrol. Inflamm.
Allergy Drug Targets 6: 168–73.
44. Carter, L. G., J. A. D’Orazio, and K. J. Pearson. 2014. Resveratrol and cancer: Focus
on in vivo evidence. Endocr. Relat. Cancer 21.
45. Baxter, R. A. 2008. Anti-aging properties of resveratrol: Review and report of a
potent new antioxidant skin care formulation. J. Cosmet. Dermatol. 7: 2–7.
46. Falchetti, R., M. P. Fuggetta, G. Lanzilli, M. Tricarico, and G. Ravagnan. 2001.
Effects of resveratrol on human immune cell function. Life Sci. 70: 81–96.
47. Han, S.-Y., J.-Y. Bae, S.-H. Park, Y.-H. Kim, J. H. Y. Park, and Y.-H. Kang. 2013.
Resveratrol Inhibits IgE-Mediated Basophilic Mast Cell Degranulation and Passive
Cutaneous Anaphylaxis in Mice. J. Nutr. 143: 632–639.
48. Chen, J., H. Zhou, J. Wang, B. Zhang, F. Liu, J. Huang, J. Li, J. Lin, J. Bai, and R.
Liu. 2015. Therapeutic effects of resveratrol in a mouse model of HDM-induced allergic
asthma. Int. Immunopharmacol. 25: 43–48.
49. Karuppagounder, V., S. Arumugam, R. A. Thandavarayan, V. Pitchaimani, R.
Sreedhar, R. Afrin, M. Harima, H. Suzuki, M. Nomoto, S. Miyashita, K. Suzuki, and K.
Watanabe. 2014. Resveratrol attenuates HMGB1 signaling and inflammation in house
dust mite-induced atopic dermatitis in mice. Int. Immunopharmacol. 23: 617–623.
50. Baolin, L., Y. Inami, H. Tanaka, N. Inagaki, M. Iinuma, and H. Nagai. 2004.
Resveratrol inhibits the release of mediators from bone marrow-derived mouse mast cells
in vitro. Planta Med. 70: 305–309.
51. Kang, O. H., H. J. Jang, H. S. Chae, Y. C. Oh, J. G. Choi, Y. S. Lee, J. H. Kim, Y. C.
Kim, D. H. Sohn, H. Park, and D. Y. Kwon. 2009. Anti-inflammatory mechanisms of
resveratrol in activated HMC-1 cells: Pivotal roles of NF-κB and MAPK. Pharmacol.
Res. 59: 330–337.

99

52. Tanaka, T., M. Narazaki, and T. Kishimoto. 2014. IL-6 in Inflammation, Immunity,
and Disease. Cold Spring Harb. Perspect. Biol. 6: a016295–a016295.
53. Scheller, J., A. Chalaris, D. Schmidt-Arras, and S. Rose-John. 2011. The pro- and
anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta - Mol.
Cell Res. 1813: 878–888.
54. Silver, J. S., and C. A. Hunter. 2010. gp130 at the nexus of inflammation,
autoimmunity, and cancer. J. Leukoc. Biol. 88: 1145–1156.
55. Rose-John, S. 2012. Il-6 trans-signaling via the soluble IL-6 receptor: Importance for
the proinflammatory activities of IL-6. Int. J. Biol. Sci. 8: 1237–1247.
56. Schumacher, N., D. Meyer, A. Mauermann, J. Von Der Heyde, J. Wolf, J. Schwarz,
K. Knittler, G. Murphy, M. Michalek, C. Garbers, J. W. Bartsch, S. Guo, B. Schacher, P.
Eickholz, A. Chalaris, S. Rose-John, and B. Rabe. 2015. Shedding of endogenous
interleukin-6 receptor (IL-6R) is governed by a disintegrin and metalloproteinase
(ADAM) proteases while a full-length IL-6R isoform localizes to circulating
microvesicles. J. Biol. Chem. 290: 26059–26071.
57. Babon, J. J., L. N. Varghese, and N. A. Nicola. 2014. Inhibition of IL-6 family
cytokines by SOCS3. Semin. Immunol. 26: 13–19.
58. Wegiel, B., A. Bjartell, Z. Culig, and J. L. Persson. 2008. Interleukin-6 activates
PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int.
J. Cancer 122: 1521–1529.
59. Heinrich, P. C., I. Behrmann, G. Müller-Newen, F. Schaper, and L. Graeve. 1998.
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J.
334: 297–314.
60. Mauer, J., B. Chaurasia, J. Goldau, M. C. Vogt, J. Ruud, K. D. Nguyen, S. Theurich,
a C. Hausen, J. Schmitz, H. S. Brönneke, E. Estevez, T. L. Allen, A. Mesaros, L.
Partridge, M. a Febbraio, A. Chawla, F. T. Wunderlich, and J. C. Brüning. 2014.
Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia
and obesity-associated resistance to insulin. Nat. Immunol. 15: 423–30.
61. Gabay, C. 2006. Interleukin-6 and chronic inflammation. Arthritis Res. Ther. 8 Suppl
2: S3.
62. Morjaria, J. B., K. S. Babu, P. Vijayanand, A. J. Chauhan, D. E. Davies, and S. T.
Holgate. 2011. Sputum IL-6 concentrations in severe asthma and its relationship with
FEV1. Thorax 66: 537.
63. Fitzpatrick, A. M., M. Higgins, F. Holguin, L. A. S. Brown, and W. G. Teague. 2010.
The molecular phenotype of severe asthma in children. J. Allergy Clin. Immunol. 125.
64. Yokoyama, A., N. Kohno, S. Fujino, H. Hamada, Y. Inoue, S. Fujioka, S. Ishida, and
K. Hiwada. 1995. Circulating interleukin-6 levels in patients with bronchial asthma. Am.
J. Respir. Crit. Care Med. 151: 1354–8.
65. Neveu, W. A., J. L. Allard, D. M. Raymond, L. M. Bourassa, S. M. Burns, J. Y.
Bunn, C. G. Irvin, D. A. Kaminsky, and M. Rincon. 2010. Elevation of IL-6 in the
allergic asthmatic airway is independent of inflammation but associates with loss of
central airway function. Respir. Res. 11.
66. Kasperska-Zajac, A., J. Sztylc, E. Machura, and G. Jop. 2011. Plasma IL-6
concentration correlates with clinical disease activity and serum C-reactive protein
concentration in chronic urticaria patients. Clin. Exp. Allergy 41: 1386–1391.
67. Fujii, K., K. Konishi, Y. Kanno, and N. Ohgou. 2001. Acute urticaria with elevated

100

circulating interleukin-6 is resistant to anti-histamine treatment. J. Dermatol. 28: 248–
250.
68. Brockow, K., C. Akin, M. Huber, and D. D. Metcalfe. 2005. IL-6 levels predict
disease variant and extent of organ involvement in patients with mastocytosis. Clin.
Immunol. 115: 216–23.
69. Mayado, A., C. Teodosio, A. C. Garcia-Montero, A. Matito, A. Rodriguez-Caballero,
J. M. Morgado, C. Muñiz, M. Jara-Acevedo, I. Álvarez-Twose, L. Sanchez-Munõz, S.
Matarraz, C. Caldas, J. I. Munoz-Gonzalez, L. Escribano, and A. Orfao. 2016. Increased
IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk
of disease progression. Leukemia 30: 124–130.
70. Kinoshita, T., N. Sawai, E. Hidaka, T. Yamashita, and K. Koike. 1999. Interleukin-6
directly modulates stem cell factor-dependent development of human mast cells derived
from CD34(+) cord blood cells. Blood 94: 496–508.
71. Oskeritzian, C. A., W. Zhao, A. L. Pozez, N. M. Cohen, M. Grimes, and L. B.
Schwartz. 2004. Neutralizing endogenous IL-6 renders mast cells of the MCT type from
lung, but not the MCTC type from skin and lung, susceptible to human recombinant IL-4induced apoptosis. J. Immunol. 172: 593–600.
72. Misiak-TŁoczek, A., and E. BrzeziŃska-BŁaszczyk. 2009. IL-6, but not IL-4,
stimulates chemokinesis and TNF stimulates chemotaxis of tissue mast cells:
Involvement of both mitogen-activated protein kinases and phosphatidylinositol 3-kinase
signalling pathways. APMIS 117: 558–567.
73. Desai, A., M. Y. Jung, A. Olivera, A. M. Gilfillan, C. Prussin, A. S. Kirshenbaum, M.
A. Beaven, and D. D. Metcalfe. 2016. IL-6 promotes an increase in human mast cell
numbers and reactivity through suppression of suppressor of cytokine signaling 3. J.
Allergy Clin. Immunol. 137: 1863–1871e6.
74. Breier, G. 2000. Angiogenesis in embryonic development--a review. Placenta 21
Suppl A: S11–S15.
75. Tonnesen, M. G., X. Feng, and R. A. F. Clark. 2000. Angiogenesis in wound healing.
J. Investig. Dermatology Symp. Proc. 5: 40–46.
76. Zygmunt, M., F. Herr, K. Münstedt, U. Lang, and O. D. Liang. 2003. Angiogenesis
and vasculogenesis in pregnancy. In European Journal of Obstetrics Gynecology and
Reproductive Biology vol. 110.
77. Hillen, F., and A. W. Griffioen. 2007. Tumour vascularization: Sprouting
angiogenesis and beyond. Cancer Metastasis Rev. 26: 489–502.
78. Imhof, B. A., and M. Aurrand-Lions. 2006. Angiogenesis and inflammation face off.
Nat. Med. 12: 171–172.
79. Chen, L., A. Endler, and F. Shibasaki. 2009. Hypoxia and angiogenesis: Regulation
of hypoxia-inducible factors via novel binding factors. Exp. Mol. Med. 41: 849–857.
80. Krock, B. L., N. Skuli, and M. C. Simon. 2011. Hypoxia-Induced Angiogenesis:
Good and Evil. Genes and Cancer 2: 1117–1133.
81. Lin, C., R. McGough, B. Aswad, J. Block, and R. Terek. 2004. Hypoxia induces HIF1-alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J. Orthop. Res.
22: 1175–1181.
82. Lobov, I. B., R. A. Renard, N. Papadopoulos, N. W. Gale, G. Thurston, G. D.
Yancopoulos, and S. J. Wiegand. 2007. Delta-like ligand 4 (Dll4) is induced by VEGF as
a negative regulator of angiogenic sprouting. Proc. Natl. Acad. Sci. 104: 3219–3224.

101

83. Greer, S. N., J. L. Metcalf, Y. Wang, and M. Ohh. 2012. The updated biology of
hypoxia-inducible factor. EMBO J. 31: 2448–2460.
84. Raza, A., M. J. Franklin, and A. Z. Dudek. 2010. Pericytes and vessel maturation
during tumor angiogenesis and metastasis. Am. J. Hematol. 85: 593–598.
85. Ucuzian, A. A., A. A. Gassman, A. T. East, and H. P. Greisler. 2010. Molecular
mediators of angiogenesis. J. Burn Care Res. 31: 158–175.
86. Tímár, J., B. Döme, K. Fazekas, Á. Janovics, and S. Paku. 2001. Angiogenesisdependent diseases and angiogenesis therapy. Pathol. Oncol. Res. 7: 85–94.
87. Heng Wong, S., and J. M. Lord. 2004. Factors underlying chronic inflammation in
rheumatoid arthritis. Arch Immunol Ther Exp 52: 379–388.
88. Huang, B., Z. Lei, G. M. Zhang, D. Li, C. Song, B. Li, Y. Liu, Y. Yuan, J. Unkeless,
H. Xiong, and Z. H. Feng. 2008. SCF-mediated mast cell infiltration and activation
exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood
112: 1269–1279.
89. Oskeritzian, C. A. 2012. Mast Cells and Wound Healing. Adv. Wound Care 1: 23–28.
90. de Souza Junior, D. A., A. C. Santana, E. Z. M. da Silva, C. Oliver, and M. C. Jamur.
2015. The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis.
Biomed Res. Int. 2015: 1–13.
91. Crivellato, E., B. Nico, and D. Ribatti. 2009. Mast cell contribution to tumor
angiogenesis: A clinical approach. Eur. Cytokine Netw. 20: 197–206.
92. Ribatti, D., E. Crivellato, L. Candussio, B. Nico, A. Vacca, L. Roncali, and F.
Dammacco. 2001. Mast cells and their secretory granules are angiogenic in the chick
embryo chorioallantoic membrane. Clin. Exp. Allergy 31: 602–608.
93. De Souza Junior, D. A., V. M. Mazucato, A. C. Santana, C. Oliver, and M. C. Jamur.
2017. Mast cells interact with endothelial cells to accelerate in vitro angiogenesis. Int. J.
Mol. Sci. 18.
94. Feoktistov, I., S. Ryzhov, A. E. Goldstein, and I. Biaggioni. 2003. Mast cell-mediated
stimulation of angiogenesis: Cooperative interaction between A2B and A3 adenosine
receptors. Circ. Res. 92: 485–492.
95. De Souza, D. A., A. C. Borges, A. C. Santana, C. Oliver, and M. C. Jamur. 2015.
Mast cell proteases 6 and 7 stimulate angiogenesis by inducing endothelial cells to
release angiogenic factors. PLoS One 10.
96. Wroblewski, M., R. Bauer, M. Cubas Córdova, F. Udonta, I. Ben-Batalla, K. Legler,
C. Hauser, J. Egberts, M. Janning, J. Velthaus, C. Schulze, K. Pantel, C. Bokemeyer, and
S. Loges. 2017. Mast cells decrease efficacy of anti-angiogenic therapy by secreting
matrix-degrading granzyme B. Nat. Commun. 8.
97. Eady, R. A., T. Cowen, T. F. Marshall, V. Plummer, and M. W. Greaves. 1979. Mast
cell population density, blood vessel density and histamine content in normal human skin.
Br J Dermatol 100: 623–633.
98. Schwartz, L. B., K. F. Austen, and S. I. Wasserman. 1979. Immunologic Release of
beta-Hexosaminidase and beta-Glucuronidase from Purified Rat Serosal Mast Cells. J.
Immunol. 123: 1445–1450.
99. Schwartz, L. B., R. a Lewis, D. Seldin, and K. F. Austen. 1981. Acid hydrolases and
tryptase from secretory granules of dispersed human lung mast cells. J. Immunol. 126:
1290–4.
100. Zhao, W., C. A. Oskeritzian, A. L. Pozez, and L. B. Schwartz. 2005. Cytokine

102

Production by Skin-Derived Mast Cells: Endogenous Proteases Are Responsible for
Degradation of Cytokines. J. Immunol. 175: 2635–2642.
101. Gomez, G., V. Nardone, S. Lotfi-Emran, W. Zhao, and L. B. Schwartz. 2013.
Intracellular adenosine inhibits IgE-dependent degranulation of human skin mast cells. J.
Clin. Immunol. 33: 1349–1359.
102. Kawata, R., S. T. Reddy, B. Wolner, and H. R. Herschman. 1995. Prostaglandin
synthase 1 and prostaglandin synthase 2 both participate in activation-induced
prostaglandin D2 production in mast cells. J. Immunol. (Baltimore, Md. 1950) 155: 818–
825.
103. Siraganian, R. P., J. Zhang, K. Suzuki, and K. Sada. 2001. Protein tyrosine kinase
Syk in mast cell signaling. Mol. Immunol. 38: 1229–1233.
104. Costello, P. S., M. Turner, A. E. Walters, C. N. Cunningham, P. H. Bauer, J.
Downward, and V. L. Tybulewicz. 1996. Critical role for the tyrosine kinase Syk in
signalling through the high affinity IgE receptor of mast cells. Oncogene 13: 2595–2605.
105. Zhang, J., E. H. Berenstein, R. L. Evans, and R. P. Siraganian. 1996. Transfection of
Syk protein tyrosine kinase reconstitutes high affinity IgE receptor-mediated
degranulation in a Syk-negative variant of rat basophilic leukemia RBL-2H3 cells. J.
Exp. Med. 184: 71–9.
106. Shiue, L., J. Green, O. M. Green, J. L. Karas, J. P. Morgenstern, M. K. Ram, M. K.
Taylor, M. J. Zoller, L. D. Zydowsky, and J. B. Bolen. 1995. Interaction of p72syk with
the gamma and beta subunits of the high-affinity receptor for immunoglobulin E, Fc
epsilon RI. Mol. Cell. Biol. 15: 272–81.
107. Gomez, G., C. Gonzalez-Espinosa, S. Odom, G. Baez, M. E. Cid, J. J. Ryan, and J.
Rivera. 2005. Impaired Fc RI-Dependent Gene Expression and Defective Eicosanoid and
Cytokine Production as a Consequence of Fyn Deficiency in Mast Cells. J. Immunol.
175: 7602–7610.
108. Nakano, N., C. Nishiyama, H. Yagita, A. Koyanagi, H. Akiba, S. Chiba, H. Ogawa,
and K. Okumura. 2009. Notch signaling confers antigen-presenting cell functions on mast
cells. J. Allergy Clin. Immunol. 123.
109. Kitaura, J., K. Asai, M. Maeda-Yamamoto, Y. Kawakami, U. Kikkawa, and T.
Kawakami. 2000. Akt-dependent cytokine production in mast cells. J. Exp. Med. 192:
729–740.
110. Koo, N., D. Cho, Y. Kim, H. J. Choi, and K. M. Kim. 2006. Effects of resveratrol on
mast cell degranulation and tyrosine phosphorylation of the signaling components of the
IgE receptor. Planta Med 72: 659–661.
111. Piotrowska, H., M. Kucinska, and M. Murias. 2012. Biological activity of
piceatannol: Leaving the shadow of resveratrol. Mutat. Res. - Rev. Mutat. Res. 750: 60–
82.
112. NILSSON, G., T. BLOM, M. KUSCHE‐GULLBERG, L. KJELLEN, J. H.
BUTTERFIELD, C. SUNDSTRÖM, K. NILSSON, and L. HELLMAN. 1994.
Phenotypic Characterization of the Human Mast‐Cell Line HMC‐1. Scand. J. Immunol.
39: 489–498.
113. Kempuraj, D., M. Tagen, B. P. Iliopoulou, A. Clemons, M. Vasiadi, W. Boucher, M.
House, A. Wolfberg, and T. C. Theoharides. 2008. Luteolin inhibits myelin basic proteininduced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells.
Br. J. Pharmacol. 155: 1076–1084.

103

114. Kimata, M., N. Inagaki, and H. Nagai. 2000. Effects of luteolin and other flavonoids
on IgE-mediated allergic reactions. Planta Med. 66: 25–29.
115. Kimata, M., M. Shichijo, T. Miura, I. Serizawa, N. Inagaki, and H. Nagai. 2000.
Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator
release from human cultured mast cells. Clin. Exp. Allergy 30: 501–508.
116. Tanaka, T., and R. Takahashi. 2013. Flavonoids and asthma. Nutrients 5: 2128–
2143.
117. Gualdoni, G. A., J. J. Kovarik, J. Hofer, F. Dose, D. Doberer, P. Steinberger, M.
Wolzt, and G. J. Zlabinger. 2014. Resveratrol enhances TNF-α production in human
monocytes upon bacterial stimulation. Biochim. Biophys. Acta - Gen. Subj. 1840: 95–105.
118. Scalia, S., V. Trotta, V. Iannuccelli, and A. Bianchi. 2015. Enhancement of in vivo
human skin penetration of resveratrol by chitosan-coated lipid microparticles. Colloids
Surfaces B Biointerfaces 135: 42–49.
119. Pando, D., M. Matos, G. Gutiérrez, and C. Pazos. 2015. Formulation of resveratrol
entrapped niosomes for topical use. Colloids Surfaces B Biointerfaces 128: 398–340.
120. Yutani, R., R. Teraoka, and S. Kitagawa. 2015. Microemulsion Using
Polyoxyethylene Sorbitan Trioleate and Its Usage for Skin Delivery of Resveratrol to
Protect Skin against UV-Induced Damage. Chem. Pharm. Bull. 63: 741–745.
121. Friedrich, R. B., B. Kann, K. Coradini, H. L. Offerhaus, R. C. R. Beck, and M.
Windbergs. 2015. Skin penetration behavior of lipid-core nanocapsules for simultaneous
delivery of resveratrol and curcumin. Eur. J. Pharm. Sci. 78: 204–213.
122. Cosco, D., D. Paolino, J. Maiuolo, L. Di Marzio, M. Carafa, C. A. Ventura, and M.
Fresta. 2015. Ultradeformable liposomes as multidrug carrier of resveratrol and 5fluorouracil for their topical delivery. Int. J. Pharm. 489: 1–10.
123. Marquardt, D. L., and L. L. Walker. 2000. Dependence of mast cell IgE-mediated
cytokine production on nuclear factor-κB activity. J. Allergy Clin. Immunol. 105: 500–
505.
124. Weng, Z., A. B. Patel, S. Panagiotidou, and T. C. Theoharides. 2015. The novel
flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J. Allergy Clin.
Immunol. 135: 1044–1052.e5.
125. Manna, S. K., a Mukhopadhyay, and B. B. Aggarwal. 2000. Resveratrol suppresses
TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1,
and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J.
Immunol. 164: 6509–6519.
126. Figueiras, T. S., M. T. Neves-Petersen, and S. B. Petersen. 2011. Activation energy
of light induced isomerization of resveratrol. J. Fluoresc. 21: 1897–1906.
127. Wang, F., and S. Chatterjee. 2017. Dominant Carbons in trans- and cis-Resveratrol
Isomerization. J. Phys. Chem. B 121: 4745–4755.
128. Walle, T., F. Hsieh, M. H. DeLegge, J. E. Oatis, and U. K. Walle. 2004. High
absorption but very low bioavailability of oral resveratrol in humans. Drug Metab.
Dispos. 32: 1377–1382.
129. Traum, D., P. Timothee, J. Silver, S. Rose-John, M. Ernst, and D. F. LaRosa. 2012.
IL-10-induced gp130 expression in mouse mast cells permits IL-6 trans-signaling. J.
Leukoc. Biol. 91: 427–435.
130. Erlich, T. H., Z. Yagil, G. Kay, A. Peretz, H. Migalovich-Sheikhet, S. Tshori, H.
Nechushtan, F. Levi-Schaffer, A. Saada, and E. Razin. 2014. Mitochondrial STAT3 plays

104

a major role in IgE-antigen-mediated mast cell exocytosis. J. Allergy Clin. Immunol. 134.
131. Siegel, A. M., K. D. Stone, G. Cruse, M. G. Lawrence, A. Olivera, M. Y. Jung, J. S.
Barber, A. F. Freeman, S. M. Holland, M. O’Brien, N. Jones, L. B. Wisch, H. H. Kong,
A. Desai, O. Farber, A. M. Gilfillan, J. Rivera, and J. D. Milner. 2013. Diminished
allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in
mast cell degranulation. J. Allergy Clin. Immunol. 132.
132. Hox, V., M. P. O’Connell, J. J. Lyons, P. Sackstein, T. Dimaggio, N. Jones, C.
Nelson, M. Boehm, S. M. Holland, A. F. Freeman, D. J. Tweardy, A. Olivera, D. D.
Metcalfe, and J. D. Milner. 2016. Diminution of signal transducer and activator of
transcription 3 signaling inhibits vascular permeability and anaphylaxis. J. Allergy Clin.
Immunol. 138.
133. Xie, M., A. T. Mustovich, Y. Jiang, J. B. Trudeau, A. Ray, P. Ray, H. Hu, F.
Holguin, B. Freeman, and S. E. Wenzel. 2015. IL-27 and type 2 immunity in asthmatic
patients: Association with severity, CXCL9, and signal transducer and activator of
transcription signaling. J. Allergy Clin. Immunol. 135: 386–394.
134. Chae, S. C., C. S. Li, K. M. Kim, J. Y. Yang, Q. Zhang, Y. C. Lee, Y. S. Yang, and
H. T. Chung. 2007. Identification of polymorphisms in human interleukin-27 and their
association with asthma in a Korean population. J. Hum. Genet. 52: 355–361.
135. Wittmann, M., J. Zeitvogel, D. Wang, and T. Werfel. 2009. IL-27 is expressed in
chronic human eczematous skin lesions and stimulates human keratinocytes. J. Allergy
Clin. Immunol. 124: 81–89.
136. Artis, D., A. Villarino, M. Silverman, W. He, E. M. Thornton, S. Mu, S. Summer, T.
M. Covey, E. Huang, H. Yoshida, G. Koretzky, M. Goldschmidt, G. D. Wu, F. de
Sauvage, H. R. P. Miller, C. J. M. Saris, P. Scott, and C. a Hunter. 2004. The IL-27
receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J.
Immunol. 173: 5626–5634.
137. Li, L., Y. Yang, and R. L. Stevens. 2003. RasGRP4 regulates the expression of
prostaglandin D2 in human and rat mast cell lines. J. Biol. Chem. 278: 4725–9.
138. Redell, M. S., M. J. Ruiz, T. A. Alonzo, R. B. Gerbing, and D. J. Tweardy. 2011.
Stat3 signaling in acute myeloid leukemia: Ligand-dependent and -independent activation
and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117: 5701–
5709.
139. Marone, G., G. Varricchi, S. Loffredo, and F. Granata. 2016. Mast cells and
basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur. J.
Pharmacol. 778: 146–151.
140. Zhong, Z., Z. Wen, and J. E. Darnell. 1994. Stat3: a STAT family member activated
by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.
Science 264: 95–8.
141. Darnell, J., I. Kerr, and G. Stark. 1994. Jak-STAT pathways and transcriptional
activation in response to IFNs and other extracellular signaling proteins. Science (80-. ).
264: 1415–1421.
142. Wen, Z., Z. Zhong, and J. E. Darnell. 1995. Maximal activation of transcription by
statl and stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241–250.
143. McFarland-Mancini, M. M., H. M. Funk, A. M. Paluch, M. Zhou, P. V. Giridhar, C.
A. Mercer, S. C. Kozma, and A. F. Drew. 2010. Differences in Wound Healing in Mice
with Deficiency of IL-6 versus IL-6 Receptor. J. Immunol. 184: 7219–7228.

105

144. Castellino, A. M., and M. V. Chao. 1996. Trans-signaling by cytokine and growth
factor receptors. Cytokine Growth Factor Rev. 7: 297–302.
145. Su, H., C.-T. Lei, and C. Zhang. 2017. Interleukin-6 Signaling Pathway and Its Role
in Kidney Disease: An Update. Front. Immunol. 8.
146. Saito, H., M. Ebisawa, H. Tachimoto, M. Shichijo, K. Fukagawa, K. Matsumoto, Y.
Iikura, T. Awaji, G. Tsujimoto, M. Yanagida, H. Uzumaki, G. Takahashi, K. Tsuji, and
T. Nakahata. 1996. Selective growth of human mast cells induced by steel factor, IL-6,
and prostaglandin E2 from cord blood mononuclear cells. J. Immunol. 157.
147. Griswold, D. E., and J. L. Adams. 1996. Constitutive cyclooxygenase (COX-1) and
inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to
date. Med. Res. Rev. 16: 181–206.
148. Kothari, P., R. Pestana, R. Mesraoua, R. Elchaki, K. M. F. Khan, A. J. Dannenberg,
and D. J. Falcone. 2014. IL-6-Mediated Induction of Matrix Metalloproteinase-9 Is
Modulated by JAK-Dependent IL-10 Expression in Macrophages. J. Immunol. 192: 349–
357.
149. Boesiger, J. 1998. Mast cells can secrete vascular permeability factor/vascular
endothelial cell growth factor and exhibit enhanced release after immunoglobulin Edependent upregulation of Fcɛ receptor I expression. J. Exp. Med. 188: 1135–1145.
150. Ning, Y., P. C. Manegold, Y. K. Hong, W. Zhang, A. Pohl, G. Lurje, T. Winder, D.
Yang, M. J. LaBonte, P. M. Wilson, R. D. Ladner, and H. J. Lenz. 2011. Interleukin-8 is
associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and
in vivo in colon cancer cell line models. Int. J. Cancer 128: 2038–2049.
151. Niu, J., A. Azfer, O. Zhelyabovska, S. Fatma, and P. E. Kolattukudy. 2008.
Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription
factor, MCP-1-induced protein (MCPIP). J. Biol. Chem. 283: 14542–14551.
152. Visciano, C., F. Liotti, N. Prevete, G. Cali’, R. Franco, F. Collina, A. De Paulis, G.
Marone, M. Santoro, and R. M. Melillo. 2015. Mast cells induce epithelial-tomesenchymal transition and stem cell features in human thyroid cancer cells through an
IL-8-Akt-Slug pathway. Oncogene 34: 5175–5186.
153. McHale, C., Z. Mohammed, J. Deppen, and G. Gomez. 2018. Interleukin-6
potentiates FcεRI-induced PGD<inf>2</inf>biosynthesis and induces VEGF from human
in situ-matured skin mast cells. Biochim. Biophys. Acta - Gen. Subj. 1862.
154. Seghezzi, G., S. Patel, C. J. Ren, A. Gualandris, G. Pintucci, E. S. Robbins, R. L.
Shapiro, A. C. Galloway, D. B. Rifkin, and P. Mignatti. 1998. Fibroblast growth factor-2
(FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial
cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. J. Cell
Biol. 141: 1659–1673.
155. Lampiasi, N., A. Azzolina, G. Montalto, and M. Cervello. 2007. Histamine and
spontaneously released mast cell granules affect the cell growth of human hepatocellular
carcinoma cells. Exp. Mol. Med. 39: 284–294.
156. Hoeben, A., B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. a
De Bruijn. 2004. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev.
56: 549–580.
157. Ikenaka, Y., H. Yoshiji, S. Kuriyama, J. Yoshii, R. Noguchi, H. Tsujinoue, K.
Yanase, T. Namisaki, H. Imazu, T. Masaki, and H. Fukui. 2003. Tissue inhibitor of
metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1

106

transgenic mouse model. Int. J. Cancer 105: 340–6.
158. Zhang, S. X., J. J. Wang, G. Gao, K. Parke, and J. X. Ma. 2006. Pigment epitheliumderived factor downregulates vascular endothelial growth factor (VEGF) expression and
inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J. Mol. Endocrinol. 37:
1–12.
159. Tahergorabi, Z., and M. Khazaei. 2013. The relationship between inflammatory
markers, angiogenesis, and obesity. ARYA Atheroscler. 9: 247–253.
160. Keglowich, L. F., and P. Borger. 2015. The Three A’s in Asthma – Airway Smooth
Muscle, Airway Remodeling & Angiogenesis. Open Respir. Med. J. 9: 70–80.
161. Lee, K. Y., K. S. Lee, S. J. Park, S. R. Kim, K. H. Min, Y. H. Choe, and Y. C. Lee.
2008. Clinical significance of plasma and serum vascular endothelial growth factor in
asthma. J. Asthma 45: 735–9.
162. Lee, H. Y., K. H. Min, S. M. Lee, J. E. Lee, and C. K. Rhee. 2016. Clinical
significance of serum vascular endothelial growth factor in young male asthma patients.
Korean J. Intern. Med. .
163. Poza-Guedes, P., Y. Barrios, V. Fuentes, A. Franco, I. Sánchez-Machín, E. Alonso,
R. González Pérez, S. Infante, L. Zapatero, and V. Matheu. 2014. Downregulation of
angiogenesis factors, VEGF and PDGF, after rapid IgE desensitization and oral
immunotherapy in children with food allergy. Biomed Res. Int. 2014.
164. Huang, S. P., M. S. Wu, C. T. Shun, H. P. Wang, M. T. Lin, M. L. Kuo, and J. T.
Lin. 2004. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in
gastric carcinoma. J. Biomed. Sci. 11: 517–527.
165. Huang, Y.-H., H.-Y. Yang, S.-W. Huang, G. Ou, Y.-F. Hsu, and M.-J. Hsu. 2016.
Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAKSTAT3 Signaling in Lymphatic Endothelial Cells. PLoS One 11: e0158839.
166. Adachi, Y., C. Aoki, N. Yoshio-Hoshino, K. Takayama, D. T. Curiel, and N.
Nishimoto. 2006. Interleukin-6 induces both cell growth and VEGF production in
malignant mesotheliomas. Int. J. Cancer 119: 1303–1311.
167. Yoshimura, T., O. M. Z. Howard, T. Ito, M. Kuwabara, A. Matsukawa, K. Chen, Y.
Liu, M. Liu, J. J. Oppenheim, and J. M. Wang. 2013. Monocyte Chemoattractant Protein1/CCL2 Produced by Stromal Cells Promotes Lung Metastasis of 4T1 Murine Breast
Cancer Cells. PLoS One 8.

107

APPENDIX A: PERMISSION TO REPRINT

108

